KR101371143B1 - Composition comprising chlorella for improving liver function or relieving hangover - Google Patents
Composition comprising chlorella for improving liver function or relieving hangover Download PDFInfo
- Publication number
- KR101371143B1 KR101371143B1 KR1020100106314A KR20100106314A KR101371143B1 KR 101371143 B1 KR101371143 B1 KR 101371143B1 KR 1020100106314 A KR1020100106314 A KR 1020100106314A KR 20100106314 A KR20100106314 A KR 20100106314A KR 101371143 B1 KR101371143 B1 KR 101371143B1
- Authority
- KR
- South Korea
- Prior art keywords
- blood
- chlorella
- alcohol
- hangover
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 206010019133 Hangover Diseases 0.000 title claims abstract description 89
- 241000195649 Chlorella <Chlorellales> Species 0.000 title claims abstract description 65
- 230000003908 liver function Effects 0.000 title claims abstract description 42
- 210000004369 blood Anatomy 0.000 claims abstract description 144
- 239000008280 blood Substances 0.000 claims abstract description 144
- 230000000694 effects Effects 0.000 claims abstract description 106
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 38
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 239000004310 lactic acid Substances 0.000 claims abstract description 19
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 19
- 230000006872 improvement Effects 0.000 claims abstract description 18
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 15
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 26
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 19
- 240000006891 Artemisia vulgaris Species 0.000 claims description 15
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 15
- 241000207925 Leonurus Species 0.000 claims description 15
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 15
- 240000000249 Morus alba Species 0.000 claims description 15
- 235000008708 Morus alba Nutrition 0.000 claims description 15
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 15
- 241000018646 Pinus brutia Species 0.000 claims description 15
- 235000011613 Pinus brutia Nutrition 0.000 claims description 15
- 241000245665 Taraxacum Species 0.000 claims description 15
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 15
- 235000021419 vinegar Nutrition 0.000 claims description 15
- 239000000052 vinegar Substances 0.000 claims description 15
- 235000000832 Ayote Nutrition 0.000 claims description 14
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 14
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims description 14
- 240000005979 Hordeum vulgare Species 0.000 claims description 14
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 14
- 235000015136 pumpkin Nutrition 0.000 claims description 14
- 241000209020 Cornus Species 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 240000004244 Cucurbita moschata Species 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 241000219122 Cucurbita Species 0.000 claims description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 6
- 235000008434 ginseng Nutrition 0.000 claims description 6
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims description 5
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000012676 herbal extract Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 2
- 241000269837 Artemisia dubia Species 0.000 claims 1
- 240000008067 Cucumis sativus Species 0.000 claims 1
- 235000009849 Cucumis sativus Nutrition 0.000 claims 1
- 235000021384 green leafy vegetables Nutrition 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 160
- 206010067125 Liver injury Diseases 0.000 abstract description 15
- 231100000234 hepatic damage Toxicity 0.000 abstract description 14
- 230000008818 liver damage Effects 0.000 abstract description 14
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 206010019233 Headaches Diseases 0.000 abstract description 9
- 231100000869 headache Toxicity 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000020477 pH reduction Effects 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 6
- 239000003513 alkali Substances 0.000 abstract description 4
- 230000007661 gastrointestinal function Effects 0.000 abstract description 3
- 235000019441 ethanol Nutrition 0.000 description 158
- 239000000047 product Substances 0.000 description 57
- 235000013305 food Nutrition 0.000 description 31
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 22
- 238000005259 measurement Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000037213 diet Effects 0.000 description 11
- 235000008216 herbs Nutrition 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 10
- 230000035622 drinking Effects 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 125000003158 alcohol group Chemical group 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 230000035922 thirst Effects 0.000 description 8
- 208000007848 Alcoholism Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 235000019750 Crude protein Nutrition 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229930002875 chlorophyll Natural products 0.000 description 5
- 235000019804 chlorophyll Nutrition 0.000 description 5
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- -1 for example Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 108010025188 Alcohol oxidase Proteins 0.000 description 3
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 3
- 235000003097 Artemisia absinthium Nutrition 0.000 description 3
- 240000001851 Artemisia dracunculus Species 0.000 description 3
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 244000234609 Portulaca oleracea Species 0.000 description 3
- 235000001855 Portulaca oleracea Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010038687 Respiratory distress Diseases 0.000 description 3
- 244000000231 Sesamum indicum Species 0.000 description 3
- 235000003434 Sesamum indicum Nutrition 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 3
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000001138 artemisia absinthium Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000002395 blood acidification Effects 0.000 description 3
- 235000021329 brown rice Nutrition 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000029553 photosynthesis Effects 0.000 description 2
- 238000010672 photosynthesis Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- YZBILXXOZFORFE-UHFFFAOYSA-N 6-Methoxy-2-naphthoic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(OC)=CC=C21 YZBILXXOZFORFE-UHFFFAOYSA-N 0.000 description 1
- VZBLASFLFFMMCM-UHFFFAOYSA-N 6-methoxynaphthalene-2-carbaldehyde Chemical compound C1=C(C=O)C=CC2=CC(OC)=CC=C21 VZBLASFLFFMMCM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010001623 Alcoholic hangover Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101000880889 Drosophila melanogaster Protein dead ringer Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241001299819 Hordeum vulgare subsp. spontaneum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- RBIHPAASYUYQNM-UHFFFAOYSA-N OCl(=O)(=O)=O.OCl(=O)(=O)=O Chemical compound OCl(=O)(=O)=O.OCl(=O)(=O)=O RBIHPAASYUYQNM-UHFFFAOYSA-N 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000003826 Respiratory Acidosis Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001941 electron spectroscopy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000000408 embryogenic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-L oxaloacetate(2-) Chemical compound [O-]C(=O)CC(=O)C([O-])=O KHPXUQMNIQBQEV-UHFFFAOYSA-L 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물에 관한 것이다. 본 발명에 따른 간기능 개선 또는 숙취해소용 조성물은 혈중 알코올 농도의 저감효과 및 혈액의 산성화를 억제하는 활성(혈중 이산화탄소 및 젖산의 농도 저감효과, 알코올 섭취로 인해 산성화된 혈중 pH를 정상의 알카리로 전환시키는 효과)이 매우 우수하고, 알코올의 과다 섭취에 의한 간 손상으로부터 보호 효과, 위장 기능 개선 효과, 두통 감소 효과 등 숙취해소 효과가 매우 우수하다.The present invention relates to a liver function improvement or hangover relief composition comprising chlorella as an active ingredient. The composition for improving liver function or releasing hangover according to the present invention has an effect of reducing the blood alcohol concentration and inhibiting acidification of blood (effect of reducing the concentration of carbon dioxide and lactic acid in the blood, acidified blood pH due to alcohol intake to normal alkali). Conversion effect) is very excellent, and hangover relief effect such as protection from liver damage caused by excessive intake of alcohol, gastrointestinal function improvement effect, headache reduction effect is very excellent.
Description
본 발명은 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물 및 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 건강기능식품에 관한 것이다.
The present invention relates to a liver function improving or hangover composition comprising chlorella as an active ingredient and to a liver functional improvement or hangover relief containing chlorella as an active ingredient.
한국의 알코올 소비는 세계 최고의 수준이며, 간암이나 간경변으로 인한 사망이 한국인의 주요 사망원인이 되는 등 음주로 인한 사회경제적 및 보건학적 폐해는 엄청나며 이는 증가 추세에 있다.Korea's alcohol consumption is among the highest in the world, and the socioeconomic and health consequences of drinking alcohol are enormous and increasing, with deaths from liver cancer and cirrhosis becoming the leading cause of death for Koreans.
일반적으로 음주를 통하여 흡수된 알코올의 효과는 음주 후 약 10분 이내에 나타나기 시작하여 40∼60분이면 최고 정점에 도달하게 된다. 알코올은 식도 및 구강 점막에서 소량 흡수되고, 이후 약 10% 정도의 알코올은 위장에서, 나머지 90% 정도의 알코올은 소장에서 흡수되게 된다. 알코올의 흡수는 여러 가지 요인에 의해 결정되는데, 지방이 많은 음식물은 이동 속도가 느려 알코올의 흡수를 느리게 하며, 공복시에는 음식물과 함께 음주를 하는 경우보다 3∼4배 빨리 흡수되며, 술을 빨리 마실수록 흡수되는 속도도 증가한다. 알코올은 영양학적인 측면에서 7.1 kcal/g의 높은 열량을 발생하는 물질이지만, 함유하고 있는 열량 그대로 인체가 흡수하지는 못한다. 또한 생체 내 유용한 에너지원으로 이용되지 못하기 때문에 영양결핍을 초래할 수도 있다.In general, the effect of alcohol absorbed through drinking begins to appear within about 10 minutes after drinking and reaches a peak in 40 to 60 minutes. Alcohol is absorbed in small amounts in the esophagus and oral mucosa, after which about 10% of the alcohol is absorbed in the stomach and the remaining 90% of the alcohol is absorbed in the small intestine. The absorption of alcohol is determined by several factors. Fatty foods slow down the absorption of alcohol because of their slow moving speed. They are absorbed three to four times faster than when drinking with food on an empty stomach, and drink alcohol quickly. The more absorbed, the higher the rate. Alcohol is a substance that produces a high calorie of 7.1 kcal / g from a nutritional point of view, but the body does not absorb the calories it contains. It can also lead to malnutrition because it can not be used as a useful energy source in vivo.
과다한 알코올 섭취는 갈증, 피로감/졸음, 두통/어지러움, 오심/구토, 무력감, 복부팽만감/위장관 불쾌감 등의 숙취현상(hangover)을 유발하며, 만성적으로는 간질환, 위염, 췌장염, 고혈압, 중풍, 식도염, 당뇨병 그리고 심장병 등 많은 질환을 일으키는 것으로 보고되고 있다.Excessive alcohol consumption can cause hangovers such as thirst, fatigue / drowsiness, headache / dizziness, nausea / vomiting, helplessness, bloating / gastrointestinal discomfort. Chronic liver disease, gastritis, pancreatitis, high blood pressure, stroke, It is reported to cause many diseases such as esophagitis, diabetes and heart disease.
정상적인 상태에서 알코올을 섭취할 경우 약 10%는 호흡이나 소변을 통해 체외로 배출되고, 나머지 90%의 대부분은 위 점막이나 간에서 대사되게 된다. 이때 알코올 대사량의 약 90∼95%는 간에서 산화되어 분해되게 된다.If you consume alcohol under normal conditions, about 10% of your body is excreted through your breath or urine, and most of the remaining 90% is metabolized in your gastric mucosa or liver. At this time, about 90-95% of the alcohol metabolism is oxidized and decomposed in the liver.
알코올은 간에 존재하는 알코올탈수소효소(alcohol dehydrogenase, ADH)와 알데하이드탈수소효소(aldehyde dehydronase, ALDH)에 이해 산화되는데 우선 ADH에 의해 아세트알데하이드(Acetaldehyde)로 산화되고, 이는 알데하이드 ALDH의 작용에 의해 아세테이트(Acetate)로 산화되어 진 후 간세포 내부로 방출되어 혈액을 거쳐 근육등의 조직으로 유입되어 에너지 생성에 이용된다. 이때 이산화탄소(CO2)와 물(H2O)이 생성된다. 이산화탄소의 증가는 혈액을 산성화시키는 주요 인자로서 구토, 두통, 갈증, 오심, 혼수상태등의 숙취현상을 일어킨다. 또한 간내에 축적된 알코올의 최초 대사산물인 아세트알데하이드는 고농도의 활성 화합물로 발한(sweat), 급맥(rapid pulse), 피부발열(skin flushing), 오심(nausea), 구토(vomiting) 등을 유발하며, 이러한 이유로 대부분의 연구자들은 알코올 분해산물인 아세트알데하이드가 숙취의 원인이라고 생각하고 있다.Alcohol is oxidized to alcohol dehydrogenase (ADH) and aldehyde dehydronase (ALDH) present in the liver. First, it is oxidized to acetaldehyde by ADH, which is produced by the action of aldehyde ALDH. After oxidized by Acetate, it is released into liver cells and flows through blood to tissues such as muscles, which is used for energy production. At this time, carbon dioxide (CO 2 ) and water (H 2 O) are produced. Increased carbon dioxide is a major factor in acidifying the blood and causes hangovers such as vomiting, headache, thirst, nausea and lethargy. Acetaldehyde, the first metabolite of alcohol accumulated in the liver, is also a high concentration of active compound, causing sweat, rapid pulse, skin flushing, nausea, vomiting, etc. For this reason, most researchers believe that acetaldehyde, the alcohol breakdown product, is the cause of hangovers.
숙취 증상은 음주를 마친 후 몇 시간 안에 시작되어서 거의 하루 동안 지속되는데, 특별한 숙취의 경험은 매우 개인적인 성향과 상황적이고 소비된 알코올의 종류와 양에 의존적이다. 신체적 숙취 증상들은 두통, 피로, 빛과 소리 민감성, 근육통, 눈의 적색, 갈증, 오심, 구토 그리고 위통을 포함한다. 숙취는 빠른 심장박동, 흥분, 혈압상승 그리고 발한의 원인이 된다. 숙취의 관련된 정신적 증상들은 수면부족, 수면장소 변화, 주의력 감소, 집중력 저하, 우울, 현기증, 불안, 과민을 포함한다.Symptoms of a hangover begin within a few hours after drinking and last for almost a day. The experience of a particular hangover is very personal and depends on the situation and the type and amount of alcohol consumed. Symptoms of physical hangover include headache, fatigue, light and sound sensitivity, myalgia, redness of the eyes, thirst, nausea, vomiting and stomach pain. Hangover causes fast heartbeat, excitement, elevated blood pressure and sweating. Related mental symptoms of hangovers include sleep deprivation, changes in sleeping area, decreased attention, decreased concentration, depression, dizziness, anxiety and irritability.
이와 같이 음주 후 나타나는 숙취를 해소하기 위하여 예로부터 콩나물, 북어, 녹두 등이 음주 후의 숙취 해소용 음식으로 이용되어 왔다. 특히 콩나물에는 알코올탈수소효소(ADH)의 작용을 도와 알코올 분해를 촉진시킴으로써 간을 보호한다고 알려져 있는 아스파라긴산이 풍부하게 함유되어 있으며, 현재 아스파라긴산이 함유된 숙취해소용 음료도 시판되고 있다.In order to solve the hangover after drinking, bean sprouts, curry, mung bean have been used as food for hangover after drinking. In particular, bean sprouts are rich in aspartic acid, which is known to protect the liver by promoting the action of alcohol dehydrogenase (ADH) and promoting alcohol degradation. Currently, a hangover drink containing aspartic acid is also commercially available.
최근 음주 후 발생하는 숙취 감소 및 제거를 위한 다양한 의약품들이 개발되었으나 이들 자체의 독성이나 부작용으로 인해 보다 안전한 천연물 유래 건강음료의 개발에 많은 관심이 모아지고 있다.Recently, various drugs for reducing and eliminating hangovers after drinking have been developed, but due to their toxicity and side effects, much attention has been drawn to the development of safer natural-derived health drinks.
이에 따라, 천연식물 추출물을 이용한 숙취해소용 조성물에 대한 특허 출원이 많아지는 추세이다.
Accordingly, there is a trend of increasing patent applications for hangover composition using natural plant extracts.
이에 본 발명자들은 클로렐라-허브 복합물이 간기능 개선 및 숙취해소에 우수한 활성을 나타낸다는 사실을 확인함으로써 상기 클로렐라-허브 복합물을 간기능 개선 또는 숙취해소용 약제 또는 기능성 식품으로 사용할 수 있음을 규명하였다.Accordingly, the present inventors have confirmed that the chlorella-herb complex can be used as a medicament or functional food for improving liver function or hangover by confirming that the chlorella-herb complex exhibits excellent activity in improving liver function and relieving hangover.
따라서 본 발명의 목적은 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물을 제공하는 것이다.Therefore, an object of the present invention is to provide a composition for improving liver function or hangover, comprising chlorella as an active ingredient.
또한, 본 발명의 다른 목적은 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 건강기능식품을 제공하는 것이다.
In addition, another object of the present invention is to provide a health functional food for liver function improvement or hangover relief comprising chlorella as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 클로렐라 추출물; 및 솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유로 이루어진 군에서 선택된 어느 한 종 이상의 허브 추출물을 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물을 제공한다.In order to achieve the above object, the present invention is a chlorella extract; And it provides a composition for improving liver function or hangover, including any one or more herbal extracts selected from the group consisting of pine needles, mulberry leaves, barley shoots, pumpkin, thorny ginseng, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion and cornus as an active ingredient .
또한, 본 발명은 클로렐라의 건조분말; 및 솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유로 이루어진 군에서 선택된 어느 한 종 이상의 허브 건조분말을 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물을 제공한다.In addition, the present invention is a dry powder of chlorella; And pine needles, mulberry leaves, barley shoots, pumpkin, thorny scabies, mugwort, eoseongcho, Sinseoncho, motherwort, dandelion and cornus oil, any one or more herbs dried powder selected from the group as an active ingredient for improving liver function or hangover do.
본 발명의 일실시예에 있어서, 상기 조성물 전체 100중량부에 대하여 클로렐라 40 ~ 70 중량부, 솔잎 9 ~ 18 중량부, 뽕잎 4.5 ~ 10.5 중량부, 보리순 3 ~ 6 중량부, 호박 3 ~ 6 중량부, 가시오가피 1.5 ~ 3 중량부, 쑥 1.5 ~ 1.5 중량부, 어성초 1.5 ~ 3 중량부, 신선초 1.5 ~ 3 중량부, 익모초 1.5 ~ 3 중량부, 민들레 1.5 ~ 3 중량부 및 산수유 1.5 ~ 3 중량부를 포함할 수 있다.In one embodiment of the present invention, 40 to 70 parts by weight of chlorella, 9 to 18 parts by weight of pine needles, 4.5 to 10.5 parts by weight of mulberry leaves, 3 to 6 parts by weight of barley sprout, 3 to 6 parts by weight, based on 100 parts by weight of the composition 1, 3 parts by weight, wormwood 1.5 to 1.5 parts by weight, mugwort vinegar 1.5 to 3 parts by weight, fresh vinegar 1.5 to 3 parts by weight, motherwort 1.5 to 3 parts by weight, dandelion 1.5 to 3 parts by weight, and corn coriander 1.5 to 3 parts by weight It may include.
본 발명의 일실시예에 있어서, 상기 추출물은 물 또는 유기용매로 추출하여 수득한 것일 수 있다.In one embodiment of the present invention, the extract may be obtained by extraction with water or an organic solvent.
본 발명의 일실시예에 있어서, 상기 건조분말은 100℃ 이하의 온도에서 건조시켜 분말화한 것일 수 있다.In one embodiment of the present invention, the dry powder may be powdered by drying at a temperature of less than 100 ℃.
본 발명의 일실시예에 있어서, 상기 조성물은 인진쑥, 발아현미, 쇠미름, 황버섯 및 참깨가루로 이루어진 군에서 선택된 어느 한 종 이상의 추출물 또는 건조분말을 더 포함할 수 있다.In one embodiment of the present invention, the composition may further comprise any one or more extracts or dry powder selected from the group consisting of phosphorus mugwort, germinated brown rice, purslane, yellow mushroom and sesame powder.
본 발명의 일실시예에 있어서, 혈중 이산화탄소의 농도를 감소시키는 활성, 혈중 pH를 증가시키는 활성 및 혈중 젖산 농도를 감소시키는 활성을 나타낼 수 있다.In one embodiment of the present invention, it can exhibit the activity of reducing the concentration of carbon dioxide in the blood, the activity of increasing the pH of the blood and the activity of reducing the concentration of lactic acid in the blood.
본 발명의 일실시예에 있어서, 상기 조성물은 혈중의 AST, ALT 및 r-GTP 농도를 감소시키는 활성을 나타낼 수 있다.In one embodiment of the invention, the composition may exhibit activity to reduce the concentration of AST, ALT and r-GTP in the blood.
본 발명의 일실시예에 있어서, 상기 조성물은 알코올 탈수소효소(ADH)의 활성을 감소시키거나 알데하이드 탈수소효소(ALDH)의 활성을 감소시킬 수 있다.In one embodiment of the present invention, the composition may reduce the activity of alcohol dehydrogenase (ADH) or reduce the activity of aldehyde dehydrogenase (ALDH).
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 건강기능식품을 제공한다.
In addition, the present invention provides a health functional food for liver function improvement or hangover relief comprising the composition as an active ingredient.
본 발명에 따른 간기능 개선 또는 숙취해소용 조성물은 혈중 알코올 농도의 저감효과 및 혈액의 산성화를 억제하는 활성(혈중 이산화탄소 및 젖산의 농도 저감효과, 알코올 섭취로 인해 산성화된 혈중 pH를 정상의 알카리로 전환시키는 효과)이 매우 우수하고, 알코올의 과다 섭취에 의한 간 손상으로부터 보호 효과, 위장 기능 개선 효과, 두통 감소 효과 등 숙취해소 효과가 매우 우수하다. 또한, 본 발명은 천연물질을 사용하여 생체 안정성이 우수하기 때문에 종래의 숙취해소제들에 비해 독성으로 인한 각종 부작용을 유발하지 않으므로 간기능 개선 또는 숙취의 예방, 해소 및 기능성 식품의 제조에 유용하게 사용할 수 있다.
The composition for improving liver function or releasing hangover according to the present invention has an effect of reducing the blood alcohol concentration and inhibiting acidification of blood (effect of reducing the concentration of carbon dioxide and lactic acid in the blood, acidified blood pH due to alcohol intake to normal alkali). Conversion effect) is very excellent, and hangover relief effect such as protection from liver damage caused by excessive intake of alcohol, gastrointestinal function improvement effect, headache reduction effect is very excellent. In addition, since the present invention is excellent in bio stability using natural substances, it does not cause various side effects due to toxicity compared to the conventional hangover relievers, so it is useful for improving liver function or preventing hangover, eliminating hangovers and preparing functional foods. Can be used.
본 발명은 클로렐라의 신규한 용도에 관한 것으로서, 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물을 제공함에 그 특징이 있다.The present invention relates to a novel use of chlorella, and is characterized by providing a composition for improving liver function or hangover, comprising chlorella as an active ingredient.
본 발명의 “클로렐라(chlorella)”는 녹조식물 클로렐라과에 속하는 담수조류로, 지름 10㎛ 이하의 구형 또는 타원형의 단세포 식물이며, 녹민물·습지 등에서 흔히 볼 수 있다. 현재 약 10종이 알려져 있으며, 무성생식에 의해서 증식하고 광합성에 의해서 몸의 구성물질이 증가하면 딸세포를 형성하는 등 유성생식에 비해서 고능률적이며, 광합성을 이루어 유기물을 만드는데, 광합성 때의 태양 에너지의 이용률이 높고, 단백질 함유량이 높다는 특징이 있다. 특히 클로렐라는 적당한 조건하에서는 하루에 약 10배나 증가하기 때문에 연간 유기물의 생산량이 벼의 약 8배에 해당한다. 또한 배양조건에 따라서 지방은 20~80%, 단백질은 90%까지, 그리고 탄수화물은 37%까지 함량을 높일 수 있어서, 이를 대량으로 배양하여 인간의 식량문제를 해결하고자 연구되어 왔다. 그러나 개체가 너무 작고, 그대로 먹으면 소화가 잘 안 되며, 건조 클로렐라에는 특유한 냄새가 있어 식품에 첨가하면 맛을 저하시킨다는 단점이 있어 식품으로 개발되지 못하고 있다가 최근 들어 무균순수 배양으로 소화흡수율을 높인 건강보조식품과 유제품 등이 개발 및 이용되고 있다.The "chlorella" of the present invention is a freshwater algae belonging to the green algae Chlorellaaceae, and is a spherical or oval single-celled plant having a diameter of 10 µm or less, and is commonly found in rusted water and wetlands. Currently, about 10 species are known, which are more efficient than sexual reproduction such as proliferation by asexual reproduction and the increase of constituents of the body by photosynthesis, forming daughter cells, making organic matter by photosynthesis. This is characterized by high and high protein content. In particular, chlorella increases about 10 times per day under moderate conditions, so the annual production of organic matter is about 8 times that of rice. In addition, depending on the culture conditions can increase the content of fat 20 ~ 80%, protein 90%, and carbohydrates 37%, has been studied to solve the food problem of human by culturing in large quantities. However, the individual is too small, it is difficult to digest if eaten as it is, dry chlorella has a peculiar smell has a disadvantage of lowering the taste when added to food has not been developed as a food, but recently increased the absorption of digestion by sterile pure water culture Supplements and dairy products are being developed and used.
그 밖에 클로렐라를 간접적으로 식품으로 이용하거나 다른 식품에 섞어 넣는 방안도 연구되어, 이를테면 젖산균 따위 미생물의 발육을 촉진시키는 데 이용하거나, 오염된 물을 정화하는 데 이용되기도 하며, 가축의 사료에 섞어 넣어 이용하기도 한다. 클로렐라는 고영양의 차세대 식량자원일 뿐만 아니라 체질개선, 혈전개선, 면역력 증가에 의한 항암효과, 중금속의 독성중화 및 배성효과 등의 기능성을 입증 받아 전 세계적으로 수요가 지속적으로 늘어나고 있는 추세이다.In addition, indirect use of chlorella as food or incorporation into other foods has been studied, for example, to promote the development of microorganisms such as lactic acid bacteria, or to purify contaminated water, or to mix it with livestock feed. Also used. Chlorella is not only a high-nutrition food resource of the next generation, but also has been steadily increasing all over the world as it has proved its functions such as constitution improvement, thrombosis improvement, anti-cancer effect by increased immunity, toxic neutralization and embryogenic effect of heavy metals.
그러나 이러한 클로렐라의 음주로 인한 알코올성 간손상 및 숙취를 개선 또는 억제하는 효과에 대한 연구는 미미한 실정이다.However, studies on the effects of improving or inhibiting alcoholic liver damage and hangover caused by drinking chlorella are insignificant.
이에 본 발명자들은 생체에 부작용이 없으면서도 단백질과 엽록소를 풍부히 함유하고 있는 클로렐라를 이용하여 알코올에 의한 숙취 및 간기능 장애 또는 임상적 현상(혈액의 산성화 등)을 억제 또는 개선하는 약리학적 효과를 실험한 결과, 클로렐라를 포함하는 조성물이 우수한 숙취 억제 활성, 간손상 억제 활성 및 혈액의 산성화 억제 활성을 통해 간기능 장애를 개선하고, 숙취를 해소하는데 우수한 효과를 나타낸다는 사실을 규명하였다.Therefore, the present inventors experimented with the pharmacological effect of inhibiting or improving hangover and liver dysfunction or clinical phenomenon (eg, acidification of blood) by using chlorella containing protein and chlorophyll abundantly without side effects in living body. As a result, it was found that the composition containing chlorella shows an excellent effect in improving liver dysfunction and relieving hangover through the excellent hangover inhibitory activity, liver damage inhibitory activity and blood acidification inhibitory activity.
따라서 본 발명은 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물을 제공할 수 있다.Therefore, the present invention can provide a composition for improving liver function or relieving hangover, including chlorella as an active ingredient.
본 발명에 따른 간기능 개선 또는 숙취해소용 조성물은 구체적으로 클로렐라 추출물; 및 솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유로 이루어진 군에서 선택된 어느 한 종 이상의 허브 추출물을 유효성분으로 포함하며, 또한 클로렐라 건조분말; 및 솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유로 이루어진 군에서 선택된 어느 한 종 이상의 허브 건조분말을 유효성분으로 포함한다.Liver function improvement or hangover composition according to the present invention is specifically chlorella extract; And one or more herbal extracts selected from the group consisting of pine needles, mulberry leaves, barley shoots, pumpkins, thorny ginsengs, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion and cornus as an active ingredient, and also dry chlorella powder; And at least one herb dry powder selected from the group consisting of pine needles, mulberry leaves, barley shoots, pumpkins, thorny ginseng, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion and cornus as an active ingredient.
본 발명의 조성물은 클로렐라와 각종 허브 물질의 추출물 또는 건조분말을 사용하는 것이 바람직하다.The composition of the present invention preferably uses an extract or dry powder of chlorella and various herbal substances.
본 발명에서 클로렐라는 환경 친화적으로 자연 배양한 것이라면 모두 사용가능하며, 예를 들어 조단백질은 건조 중량의 27 ~ 28%, 엽록소는 건조중량의 57.5 ~ 59%, 철은 건조중량의 67.5 ~ 69%, 총페오프르바이드는 40% 이하가 포함되어 있는 것을 사용할 수 있으나, 이에 한정되는 것은 아니다. In the present invention, chlorella can be used as long as environmentally friendly natural culture, for example, crude protein is 27 to 28% of the dry weight, chlorophyll is 57.5 to 59% of the dry weight, iron is 67.5 to 69% of the dry weight, Total ferbibiide may be used that contains less than 40%, but is not limited thereto.
본 발명에서 정의되는 “허브”는 예로부터 약이나 향료로 써 온 약초 식물을 일컫는 말로, 솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레, 산수유, 인진쑥, 발아현미, 쇠미름, 황버섯, 참깨가루 등을 모두 포함한다.“Herb” as defined in the present invention refers to herbal plants that have been used as medicines or spices since ancient times, pine needles, mulberry leaves, barley sprouts, pumpkins, thorns, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion, cornus, injin mugwort, germinated brown rice, Includes purslane, yellow mushrooms, and sesame powder.
본 발명에서 정의되는“추출물”은 당업계에 공지된 추출 및 분리하는 방법을 사용하고 적절한 용매를 이용하여 천연 원료로부터 추출 및 분리하여 수득한 것이며, 예를 들어, 클로렐라 또는 천연 허브의 조추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함한다."Extract" as defined in the present invention is obtained by extraction and separation from natural raw materials using extraction and separation methods known in the art and using a suitable solvent, for example, crude extracts of chlorella or natural herbs, It includes both polar solvent soluble extracts or nonpolar solvent soluble extracts.
상기 추출물을 추출하기 위한 적절한 용매로는 약학적으로 허용되는 유기용매라면 어느 것을 사용해도 무방하며, 물 또는 유기용매를 사용할 수 있으며, 이에 제한되지는 않으나, 예를 들어, 정제수, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등을 포함하는 탄소수 1 내지 4의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane) 및 시클로헥산(cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있다.As a suitable solvent for extracting the extract, any pharmaceutically acceptable organic solvent may be used, and water or an organic solvent may be used, but is not limited thereto. For example, purified water and methanol Alcohols containing 1 to 4 carbon atoms, acetone, ether, benzene, chloroform, including ethanol, propanol, isopropanol, isopropanol, butanol, etc. , Various solvents such as ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination.
추출 방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나를 선택하여 사용할 수 있다. 또한, 목적하는 추출물은 추가로 통상의 분획 공정을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다. 추출물의 제조방법에는 제한이 없으며, 공지되어 있는 어떠한 방법도 이용될 수 있음은 명백하다.As the extraction method, any one of the methods such as hot water extraction method, cold extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method and compression method can be selected and used. In addition, the desired extract may be further subjected to a conventional fractionation process or may be purified using a conventional purification method. There is no limitation on the method of preparing the extract, and it is obvious that any known method may be used.
본 발명의 일실시예에서는 클로렐라 원말과 각종 허브를 100℃ 이하의 온도에서 건조시키고 분말화한 후, 일정비율로 혼합하고 정제수를 사용하여 열수 추출하였으나, 이에 제한되는 것은 아니다.In an embodiment of the present invention, the raw chlorella and various herbs are dried and powdered at a temperature of 100 ° C. or lower, mixed at a constant ratio, and hot water extracted using purified water, but is not limited thereto.
상기 클로렐라 및 각종 허브는 오랫동안 생약 및 식용으로 사용되어 오던 약재로서 이들로부터 추출된 본 발명의 추출물 역시 독성 및 부작용 등의 문제가 없다.The chlorella and various herbs have been used for a long time as a herbal medicine and edible extracts of the present invention extracted from them also have no problems such as toxicity and side effects.
본 발명에서 정의되는 “건조분말”은 클로렐라와 각종 허브 물질을 건조시킨 후 분쇄하여 얻어진 것을 사용할 수 있다. 본 발명의 일실시예에서는 클로렐라 원말과 각종 허브를 100℃ 이하의 온도에서 건조시키고 분말화한 후, 일정비율로 혼합하고 반죽하여 과립을 제조하였으나, 이에 제한되는 것은 아니다.As defined in the present invention, the "dry powder" may be one obtained by drying and then grinding chlorella and various herbal materials. In an embodiment of the present invention, the raw chlorella and various herbs are dried and powdered at a temperature of 100 ° C. or less, and then mixed and kneaded at a predetermined ratio to prepare granules, but is not limited thereto.
본 발명에 따르면 상기와 같은 클로렐라 및 각종 허브의 추출물 또는 건조분말은 다양한 조성범위 내에서 혼합될 수 있으나, 조성물 전체 100중량부에 대하여 클로렐라 40 ~ 70 중량부, 솔잎 9 ~ 18 중량부, 뽕잎 4.5 ~ 10.5 중량부, 보리순 3 ~ 6 중량부, 호박 3 ~ 6 중량부, 가시오가피 1.5 ~ 3 중량부, 쑥 1.5 ~ 1.5 중량부, 어성초 1.5 ~ 3 중량부, 신선초 1.5 ~ 3 중량부, 익모초 1.5 ~ 3 중량부, 민들레 1.5 ~ 3 중량부 및 산수유 1.5 ~ 3 중량부의 조성으로 혼합하는 것이 좋다.According to the present invention, extracts or dry powders of chlorella and various herbs as described above may be mixed within various composition ranges, but 40 to 70 parts by weight of chlorella, 9 to 18 parts by weight of pine needles, mulberry leaves 4.5 with respect to 100 parts by weight of the total composition. ~ 10.5 parts by weight, barley shoots 3 to 6 parts by weight, pumpkin 3 to 6 parts by weight, thorny skin 1.5 to 3 parts by weight, mugwort 1.5 to 1.5 parts by weight, fishery vinegar 1.5 to 3 parts by weight, fresh vinegar 1.5 to 3 parts by weight, motherwort 1.5 to 3 parts by weight, dandelion 1.5 to 3 parts by weight and cornus oil is preferably mixed in a composition of 1.5 to 3 parts by weight.
또한, 본 발명의 조성물은 인진쑥, 발아현미, 쇠미름, 황버섯 및 참깨가루로 이루어진 군에서 선택된 어느 한 종 이상의 추출물 또는 건조분말을 더 포함할 수 있다.In addition, the composition of the present invention may further comprise any one or more extracts or dry powder selected from the group consisting of jinjin wormwood, germinated brown rice, purslane, yellow mushrooms and sesame powder.
한편, 본 발명에서 상기“숙취”는 알코올 섭취 후에 나타나는 부작용, 예를 들어 두통, 어지러움, 졸음, 갈증, 전신권태, 피로감, 기억상실, 복부팽만감, 소화 불량, 오심, 구토, 설사, 빛과 소리 민감성, 근육통, 눈의 적색, 오심, 비타민 결핍 등과 같이 섭취한 혈중 알코올, 그 산화물 알데하이드, 및 혈액 이산화탄소(CO2)의 증가에 의한 혈액의 산성화(pH의 저하)에 의해 일어나는 여러 가지 생리적 부작용 모두를 의미한다.On the other hand, the "hangover" in the present invention is a side effect that appears after alcohol intake, for example headache, dizziness, drowsiness, thirst, general boredom, fatigue, memory loss, bloating, indigestion, nausea, vomiting, diarrhea, light and sound All of the physiological side effects that are caused by blood acidity (such as sensitivity, myalgia, redness of the eyes, nausea, vitamin deficiency), acidification of the blood (lowering pH) by an increase in blood carbon dioxide (CO 2 ), etc. Means.
본 발명의 일실시예에서는 SD 랫트 동물 모델을 대상으로 본 발명의 클로렐라-허브 복합물을 처리하여 혈중 알콜 농도, 혈액의 산성화(CO2, 탄산이온, pH, 젖산), 간기능 장해 임상지표(AST, ALT, r-GTP), 알코올 산화효소(ADH, ALDH) 활성에 미치는 영향을 살펴봄으로써 간기능 개선 또는 숙취해소에 유효한 효과를 갖는다는 것을 확인하였다. 그 결과, 본 발명의 클로렐라-허브 복합 조성물은 혈중 알코올 농도를 감소시키는 활성이 우수하고(실험예 3 참조), 혈중 이산화탄소 및 탄산이온의 농도를 감소시키고, 혈중 pH를 산성으로부터 정상의 알카리로 회복시키며, 혈중 젖산 농도를 감소시키는 활성이 우수하고(실험예 4 참조), 간기능 장해 임상지표인 혈중의 AST, ALT 및 r-GTP 농도를 감소시키는 활성이 우수하고(실험예 5 참조), 알코올 탈수소효소(ADH) 및 알데하이드 탈수소효소(ALDH)의 활성을 감소시키는 효과가 우수하다는 것을 알 수 있었다. 이러한 작용을 통해 본 발명의 클로렐라-허브 복합물이 간기능을 개선하고 숙취를 해소할 수 있다는 사실을 확인하였다.In one embodiment of the present invention in the SD rat animal model by treating the chlorella-hub complex of the present invention, blood alcohol concentration, blood acidification (CO 2 , carbonate ion, pH, lactic acid), hepatic impairment clinical indicators (AST , ALT, r-GTP), alcohol oxidase (ADH, ALDH) by examining the effects on the activity was confirmed to have an effective effect in improving liver function or hangover. As a result, the chlorella-hub composite composition of the present invention has excellent activity of reducing blood alcohol concentration (see Experimental Example 3), reduces the concentration of carbon dioxide and carbonate ions in blood, and restores blood pH from acid to normal alkali. Excellent in reducing blood lactate concentration (see Experimental Example 4), excellent in reducing blood AST, ALT and r-GTP concentrations (see Experimental Example 5), alcohol It was found that the effect of reducing the activity of dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) is excellent. Through this action it was confirmed that the chlorella-hub complex of the present invention can improve liver function and relieve hangover.
따라서, 본 발명에 따른 간기능 개선 또는 숙취해소용 조성물은 혈중 알코올 농도의 저감효과 및 혈액의 산성화를 억제하는 활성(혈중 이산화탄소 및 젖산의 농도 저감효과, 알코올 섭취로 인해 산성화된 혈중의 pH를 정상의 알카리로 회복시키는 효과)이 매우 우수하고, 알코올의 과다 섭취에 의한 간 손상으로부터 보호 효과, 위장 기능 개선 효과, 두통 감소 효과 등 숙취해소 효과가 매우 우수하다. Therefore, the liver function improving or hangover composition according to the present invention is to reduce the blood alcohol concentration and the activity of inhibiting blood acidification (the effect of reducing the concentration of carbon dioxide and lactic acid in the blood, normalized blood pH due to alcohol intake) Recovery effect from alkali, very good hangover relief effect from liver damage caused by excessive intake of alcohol, gastrointestinal function improvement, headache reduction effect.
이에 따라 본 발명에 따른 간기능 개선 또는 숙취해소용 조성물은 기존의 숙취해소제들에 비하여 강력하게 혈중 알코올 농도를 감소시키고, 이로 인해 발생할 수 있는 간 손상을 더욱 효과적으로 방어할 수 있으며, 장기간 알코올 섭취로 인해 일어나는 만성 알코올 중독에서 클로렐라의 섭취가 알코올 중독을 개선시키는 효과가 있음을 확인함에 따라 효과적인 숙취해소제로서 개발의 가능성이 충분하다는 것을 입증하였다.Accordingly, the liver function improving or hangover composition according to the present invention can reduce blood alcohol concentration strongly compared to the conventional hangover relievers, it can more effectively defend against liver damage that may be caused, and alcohol consumption for a long time As a result of confirming that the intake of chlorella has an effect of improving alcoholism in chronic alcoholism caused by the disease, it is proved that the possibility of development as an effective hangar relievers is sufficient.
그러므로 본 발명에 따른 클로렐라-허브 복합물을 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물은 약학적 조성물로 사용될 수 있다.Therefore, the composition for improving liver function or hangover, including the chlorella-herb complex according to the present invention as an active ingredient, may be used as a pharmaceutical composition.
본 발명에 따른 간기능 개선 또는 숙취해소용 조성물은 약학적으로 유효한 양의 클로렐라-허브 복합물을 단독으로 포함하거나 하나 이상의 약학적으로 허용되는 담체, 부형제 또는 희석제를 포함할 수 있다. 상기에서 약학적으로 유효한 양이란 간손상 또는 숙취의 증상을 예방, 개선 및 치료하기에 충분한 양을 말한다.The liver function improving or hangover composition according to the present invention may contain a pharmaceutically effective amount of chlorella-hub complex alone or may include one or more pharmaceutically acceptable carriers, excipients or diluents. The pharmaceutically effective amount herein refers to an amount sufficient to prevent, ameliorate and treat the symptoms of liver damage or hangover.
본 발명에 따른 클로렐라-허브 복합물의 약학적으로 유효한 양은 0.5 ~ 100 mg/day/체중kg, 바람직하게는 1 ~ 50 mg/day/체중kg이다. 그러나 상기 약학적으로 유효한 양은 간손상 또는 숙취 증상의 정도, 환자의 연령, 체중, 건강상태, 성별, 투여 경로 및 치료기간 등에 따라 적절히 변화될 수 있다.The pharmaceutically effective amount of the chlorella-hub complex according to the invention is 0.5-100 mg / day / kg body weight, preferably 1-50 mg / day / kg body weight. However, the pharmaceutically effective amount may be appropriately changed depending on the degree of liver injury or hangover symptoms, the age, weight, health condition, sex, route of administration and duration of treatment of the patient.
또한, 상기에서약학적으로 허용되는이란 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 위장 장애, 현기증과 같은 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 조성물을 말한다. 상기 담체, 부형제 및 희석제의 예로는, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 또한, 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다. In addition, the pharmaceutically acceptable means a composition which is physiologically acceptable and does not cause an allergic reaction such as gastrointestinal disorders, dizziness or the like when administered to humans. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. Further, it may further include a filler, an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.
또한, 본 발명의 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 공지된 방법을 사용하여 제형화될 수 있다. 제형은 분말, 과립, 환, 정제, 캡슐, 에멀젼, 액상, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 멸균 주사용액, 멸균 분말의 형태일 수 있다. In addition, the compositions of the present invention may be formulated using methods known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal. The formulations may be in the form of powders, granules, pills, tablets, capsules, emulsions, liquids, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.
본 발명에 따른 간기능 개선 또는 숙취해소용 조성물은 경구, 경피, 피하, 정맥 또는 근육을 포함한 여러 경로를 통해 투여될 수 있으며, 활성 성분의 투여량은 투여 경로, 환자의 연령, 성별, 체중 및 환자의 중증도 등의 여러 인자에 따라 적절히 선택될 수 있다. The composition for improving or relieving liver function according to the present invention may be administered through various routes including oral, transdermal, subcutaneous, intravenous or muscle, and the dosage of the active ingredient is determined by the route of administration, age, sex, weight and It may be appropriately selected depending on various factors such as the severity of the patient.
또한, 본 발명의 간기능 개선 또는 숙취해소용 조성물은 간손상을 예방, 개선 또는 치료하여 간기능을 개선하고, 숙취를 해소하는 효과를 가지는 공지의 화합물과 병행하여 투여할 수 있다.In addition, the liver function improving or hangover composition of the present invention can be administered in parallel with known compounds having the effect of preventing, improving or treating liver damage to improve liver function and relieve hangover.
따라서 본 발명은 클로렐라-허브 복합물을 유효성분으로 포함하는 조성물을 포함하는 간기능 개선 및 숙취 증상을 예방 및 치료할 수 있는 약제를 제공할 수 있다.Therefore, the present invention can provide a medicament capable of preventing and treating liver improvement and hangover symptoms, including a composition comprising a chlorella-herb complex as an active ingredient.
나아가 본 발명에 따른 간기능 개선 또는 숙취해소용 조성물은 상기 기술한 바와 같이 간기능 개선 및 숙취해소를 위한 약학적 조성물로 사용할 수 있을 뿐만 아니라, 간기능 개선 및 숙취해소용 건강기능식품의 제조를 위한 식품용 조성물로도 사용할 수 있다.Furthermore, the liver function improvement or hangover relieving composition according to the present invention can be used as a pharmaceutical composition for improving liver function and hangover as described above, as well as the preparation of liver functional improvement and hangover rehabilitation health functional foods. It can also be used as a food composition for.
그러므로 본 발명은 클로렐라-허브 복합물을 유효성분으로 포함하는 간기능 개선 및 숙취해소용 식품용 조성물을 제공할 수 있다. Therefore, the present invention can provide a composition for improving liver function and relieving hangover, including a chlorella-herb complex as an active ingredient.
본 발명에 따른 상기 식품용 조성물은 간기능 개선 및 숙취해소에 효과가 있는 식품, 예컨대, 식품의 주원료, 부원료, 식품 첨가제, 기능성 식품 또는 음료로 용이하게 활용할 수 있다.The food composition according to the present invention can be easily utilized as a food, for example, a main ingredient, an auxiliary ingredient, a food additive, a functional food or a drink, which is effective in improving liver function and relieving hangover.
본원에서 상기 “식품”이란, 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서, 식품, 식품 첨가제, 기능성 식품 및 음료를 모두 포함하는 것을 말한다. As used herein, the term “food” refers to a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through a certain processing step, It includes all foods, food additives, functional foods and drinks.
본원발명에 따른 간기능 개선 및 숙취해소를 위한 식품용 조성물을 첨가할 수 있는 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 기능성 식품 등이 있다. 추가로, 본원발명에서 식품에는 특수영양식품(예, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 빵류, 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 캔디류, 쵸코렛류, 껌류, 아이스크림류, 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실 음료, 채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면 스프 등)을 포함하나 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다. Foods to which the composition for food for improving liver function and hangover according to the present invention can be added include, for example, various foods, beverages, gums, teas, vitamin complexes, functional foods, and the like. In addition, in the present invention, the food may include special nutritive foods (e.g., crude oil, spirits, baby food, etc.), meat products, fish meat products, tofu, mackerel, noodles (Such as soy sauce, soybean paste, kochujang, mixed potatoes), sauces, confectionery (eg, snacks), candies, chocolate, gums, ice cream, milk products (eg, fermented milk, cheese, But are not limited to, pickled foods (various kinds of kimchi, pickles, etc.), beverages (e.g., fruit drinks, vegetable beverages, beverages, fermented beverages and the like) and natural seasonings (e.g. The food, beverage or food additive may be prepared by a conventional production method.
또한, 상기 “기능성 식품”이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체내조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미하며, 구체적으로는 건강 기능성 식품일 수 있다. 상기 기능성 식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다. The above-mentioned " functional food " refers to a food group which is imparted with added value to function and express the function of the food by physical, biochemical or biotechnological techniques, or to control the bio-defense rhythm of the food composition, Refers to a food prepared by processing a body so as to sufficiently express the body's control function on the body, such as recovery, and the like. Specifically, it may be a health functional food. The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.
또한, 본원발명에서 상기“음료”란 갈증을 해소하거나 맛을 즐기기 위하여 마시는 것의 총칭을 의미하며 기능성 음료를 포함한다. 상기 음료는 지시된 비율로 필수 성분으로서 상기 간기능 개선 또는 숙취해소를 위한 조성물을 포함하는 것 외에 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. In addition, in the present invention, the "beverage" refers to a generic term for drinking to quench thirst or to enjoy a taste and includes a functional drink. The beverage contains, as an essential ingredient, the composition for improving the liver function or hangover, as an essential ingredient, and there are no special limitations on the other ingredients, and various flavors or natural carbohydrates as additional ingredients are included as in the general beverage. can do.
나아가 상기 기술한 것 이외에 본원발명의 간기능 개선 또는 숙취해소용 조성물을 함유하는 식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있으며, 상기 성분은 독립적으로 또는 조합하여 사용할 수 있다. Furthermore, in addition to the above, foods containing the composition for improving liver function or hangover of the present invention include various nutrients, vitamins, minerals (electrolytes), synthetic flavors, and natural flavoring agents, such as colorants and fillers (cheese). , Chocolate and the like), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The components can be used independently or in combination.
따라서 본 발명은 간기능 개선 또는 숙취해소 효과를 나타내는 클로렐라-허브 복합물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강보조식품을 제공할 수 있다.Therefore, the present invention can provide a dietary supplement comprising a chlorella-herb complex and a food supplement acceptable food supplement additive exhibiting an effect of improving liver function or hangover.
상기 건강보조식품의 종류로는 이에 제한되지는 않으나, 분말, 과립, 정제, 캡슐 또는 음료 형태일 수 있다.The type of dietary supplement is not limited thereto, but may be in the form of powder, granules, tablets, capsules, or beverages.
또한, 본원발명의 간기능 개선 또는 숙취해소를 위한 식품용 조성물을 함유하는 식품에 있어서, 상기 본 발명에 따른 조성물의 양은 전체 식품 중량의 0.001중량% 내지 90중량%로 포함할 수 있으며, 바람직하게는 0.1중량% 내지 40중량%로 포함할 수 있고, 음료의 경우, 100㎖를 기준으로 0.001g 내지 2g, 바람직하게는 0.01g 내지 0.1g의 비율로 포함할 수 있으나, 건강 및 위생을 목적으로 하거나 건강 조절을 목적으로 하는 장기간 섭취의 경우에는 상기 범위 이하일 수 있으며, 유효성분은 안전성 면에서 아무런 문제가 없기 때문에 상기 범위 이상의 양으로 사용될 수 있으므로 상기 범위에 한정되는 것은 아니다.
In addition, in a food containing a composition for food for improving liver function or relieving hangover of the present invention, the amount of the composition according to the present invention may comprise from 0.001% to 90% by weight of the total food weight, preferably May be included in an amount of 0.1% by weight to 40% by weight, and in the case of a beverage, it may be included in a ratio of 0.001g to 2g, preferably 0.01g to 0.1g based on 100ml, but for health and hygiene purposes In the case of prolonged ingestion for the purpose of health control, the range may be below the above range, and the active ingredient is not limited to the above range because the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
이하, 본 발명을 실시예 및 도면을 참조하여 상세히 설명하기로 한다. 그러나 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to embodiments and drawings. However, these examples are intended to illustrate the present invention in more detail, and the scope of the present invention is not limited to these examples.
<< 제조예Manufacturing example 1> 1>
<1-1> 재료 준비<1-1> Preparation of materials
클로렐라는 (주)한국클로렐라(경남 고성군 마암면 도전리 81-3)에서 친환경적으로 배양/제조하여 생산한 클로렐라를 구입하여 사용하였다.Chlorella Co., Ltd. purchased Chlorella produced by eco-friendly culture / manufactured by Korea Chlorella Co., Ltd. (81-3, Challenge-ri, Maam-myeon, Goseong-gun, Gyeongnam).
허브는 식품공전에서 식품으로서 적합하다고 인정하는 원료로 솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레, 산수유를 사용하였다.
Herbs used pine needles, mulberry leaves, barley sprouts, pumpkins, thorns, wormwood, eoseongcho, fresh vinegar, motherwort, dandelion, cornus as raw materials recognized as food in the Korean Food Code.
<1-2> 클로렐라-허브 혼합액의 제조<1-2> Preparation of Chlorella-Herb Mixture
클로렐라-허브 혼합액을 제조하기 위하여, 먼저 클로렐라와 각종 허브를 열풍건조기(제일제약식품기계사, 한국)로 80℃에서 6시간 동안 건조하였다. 건조된 각각의 원료를 핀밀분쇄기(제일제약식품기계사, 한국)를 사용하여 약 180 mesh로 분쇄하였다. 분쇄한 각각의 원료에 4배의 정제수를 가하여 추출농축기(동남산업, 한국)를 사용하여 80℃에서 7시간 동안 열수로 추출하여 수분량을 1/4 수준까지 증기 배출시킨 후 2.0㎛여과기(세한, 한국)로 여과하여 하기 표 1에 제시된 비율로 각각의 추출액을 혼합하여 클로렐라-허브 혼합액을 제조하였다.
In order to prepare a chlorella-hub mixture, first, chlorella and various herbs were dried at 80 ° C. for 6 hours using a hot air dryer (Jeju Pharm. Korea, Korea). Each dried raw material was pulverized to about 180 mesh using a pin mill grinder (Jeong Pharm. Food Machinery, Korea). Four times purified water was added to each of the pulverized raw materials, and extracted with hot water at 80 ° C. for 7 hours using an extracting concentrator (Dongnam Industrial, Korea). Korea) and each extract was mixed in the ratio shown in Table 1 below to prepare a chlorella-hub mixture.
<< 제조예Manufacturing example 2> 2>
클로렐라-허브 건조분말(과립) 제조Chlorella-Herb Dry Powder (Granule) Preparation
클로렐라 원말과 상기 제조예 1에서 제시된 각종 허브 즉, 클로렐라, 솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유를 건조기 100℃이하에서 건조시킨 후, 건조된 클로렐라원말 및 허브를 분쇄기에서 분쇄하였다. 분쇄된 클로렐라 및 허브를 상기 표 1에 기재된 일정 비율로 혼합하고 반죽하고, 혼합한 반죽을 과립기로 과립을 제형하고 건조하였다.
Raw chlorella and various herbs presented in Preparation Example 1, namely, chlorella, pine needles, mulberry leaves, barley sprouts, pumpkins, thorny ginseng, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion and cornus oil after drying at less than 100 ℃, dried chlorella And the herbs were ground in a mill. The pulverized chlorella and herbs were mixed and kneaded in the proportions listed in Table 1 above, and the mixed dough was formulated with a granulator and dried.
<< 실험예Experimental Example 1> 1>
클로렐라-허브 혼합물의 안정성 평가Evaluation of Stability of Chlorella-Hub Mixtures
본 발명자들은 상기 제조예 1에서 제조한 클로렐라-허브 혼합액 및 제조예 2에서 제조한 클로렐라-허브 건조분말의 안정성을 평가하기 위하여 클로렐라 세포수, 대장균수, 일반 세균수, 총엽록소, 조단백질 및 비타민 등을 분석하였다.
The inventors of the present invention, in order to evaluate the stability of the chlorella-herb mixture prepared in Preparation Example 1 and the chlorella-herb dry powder prepared in Preparation Example 2, the number of chlorella cells, E. coli, general bacteria, chlorophyll, crude protein and vitamins, etc. Was analyzed.
<1-1> 클로렐라 <1-1> Chlorella 세포(개체)수Number of Cells 측정 Measure
클로렐라-허브 혼합물을 Haemacytometer(Erma Co., Ltd., Japan)에서 현미경(Olympus Optical Co.,Ltd., Japan)으로 관찰하였다.
The chlorella-herb mixture was observed under a microscope (Olympus Optical Co., Ltd., Japan) on a Haemacytometer (Erma Co., Ltd., Japan).
<1-2> <1-2> 대장균수Escherichia coli 측정 Measure
시료 1ml을 3M PetrifilmTM E.coli/Coliform Count Plate(3M Microbiology Products, USA)에 접종하고 배양기(CO2 Incubator J 2000, Jisico, Co., Ltd., Korea)에 넣고 37℃에서 24시간 동안 배양한 후 빨간색의 집락을 형성하는 것을 E.coli/Coliform 으로 확인하고 집락수를 산정하였다.
1 ml of sample was inoculated into 3M Petrifilm TM E. coli / Coliform Count Plate (3M Microbiology Products, USA) and placed in an incubator (CO 2 Incubator J 2000, Jisico, Co., Ltd., Korea) and incubated at 37 ° C. for 24 hours. After that, red colonies were identified by E. coli / Coliform and colony counts were calculated.
<1-3> 일반 세균수 측정<1-3> General bacteria count
3M PetrifilmTM Aerobic Count Plate(3M Microbiology Products, USA), 3M PetrifilmTM Rapid Stap. aureus Count Plate(3M Microbiology Products, USA) 및 3M PetrifilmTM Yeast and Mold Count Plate(3M Microbiology Products, USA)를 각각 사용하여 3M 매뉴얼에 따라 배양기(CO2 Incubator J 2000, Jisico, Co., Ltd., Korea)에 넣어 배양한 다음 집락수를 각기 산정하여 합산하였다.
3M Petrifilm ™ Aerobic Count Plate (3M Microbiology Products, USA), 3M Petrifilm ™ Rapid Stap. aureus Count Plate (3M Microbiology Products, USA) and 3M Petrifilm TM Yeast and Mold Count Plate incubator (CO 2 Incubator J 2000, Jisico according to the manual using a 3M (3M Microbiology Products, USA), respectively, Co., Ltd., Cultivated in Korea) and the colonies were calculated and added together.
<1-4> <1-4> 총엽록소Chlorophyll
시료를 아세톤으로 추출한 후 원심분리기(MF80, 한일과학, 한국)로 3500rpm에서 분리한 다음 UV-Visible Spectrophotometers(Nicolet Evolution 300, Thermo Electron Spectroscopy Ltd., UK)를 사용하여 각각 A645와 A663에서 흡광도를 측정하였다.
Samples were extracted with acetone, separated at 3500 rpm with a centrifuge (MF80, Hanil Science, Korea), and then absorbed at A645 and A663 using UV-Visible Spectrophotometers (Nicolet Evolution 300, Thermo Electron Spectroscopy Ltd., UK). It was.
<1-5> <1-5> 조단백질Crude protein 및 비타민의 측정 And measurement of vitamins
동진생명연구원(경남 창원시)에 의뢰하여 조단백질 및 비타민의 함량을 측정하였다.
Crude protein and vitamin content were measured by requesting from Dongjin Life Research Institute (Changwon, Gyeongnam).
* 분석처 : (주)한국클로렐라 연구소 및 동진생명연구원*
* Analysis Source: Ltd. Korea Dongjin Chlorella Research Center and Institute of Life *
<< 실험예Experimental Example 2> 2>
동물투여 및 혈액채취Animal Administration and Blood Collection
본 발명자들은 상기 제조예 1에서 제조한 클로렐라-허브 혼합액이 알코올에 의해 유발되는 숙취현상에 어떠한 영향을 미치는지를 확인하기 위하여 다음과 같이 동물에 투여하고, 시험에 사용할 혈액을 채취하였다.
The present inventors administered to the animals as follows to determine how the chlorella-hub mixed solution prepared in Preparation Example 1 affects the hangover phenomenon caused by alcohol, and collected blood for use in the test.
<2-1> 투여방법<2-1> Administration method
375 ~ 395g의 SD 랫트에 클로렐라-허브 혼합액 및 기존 숙취해소제(C제품, Y제품, M제품)를 10ml/kg-BW가 되도록 경구 투여하고 30분 경과 후에 40% 알코올을 10ml/kg-BW가 되도록 경구 투여하였다. 정상 대조군으로는 물을 10ml/kg-BW가 되도록 경구 투여하고 30분 경과 후에 40% 알코올을 10ml/kg-BW가 되도록 경구 투여하였다.
375 to 395 g SD rats were orally administered with chlorella-hub mixture and conventional hangover relievers (C products, Y products, M products) to 10 ml / kg-BW and after 30 minutes, 40% alcohol was 10 ml / kg-BW Orally administered to As a normal control, water was orally administered to 10 ml / kg-BW, and 30 minutes later, 40% alcohol was orally administered to 10 ml / kg-BW.
<2-2> 혈액채취<2-2> Blood Collection
① 혈중 알코올 농도 측정용 혈액채취 : 알코올 투여 전과 투여 후 1시간, 3시간, 5시간이 지났을 때 꼬리 정맥으로부터 600 ~ 1000ml의 혈액을 채취하였고, 채취한 혈액을 3000rpm으로 10분 동안 원심분리하여 상층의 혈청을 얻었다. 얻어진 혈청의 알코올 농도를 측정한 후 추이를 확인하였다.
① Blood sampling for blood alcohol concentration measurement : 600 ~ 1000ml of blood was collected from tail vein before and after 1 hour, 3 hours, 5 hours after alcohol administration, and the collected blood was centrifuged at 3000 rpm for 10 minutes for upper layer. Serum was obtained. After measuring the alcohol concentration of the obtained serum, the trend was confirmed.
② 혈중 CO 2 및 pH 측정용 혈액채취 : 알코올을 투여한 후 24시간이 경과한 뒤에 개복하여 헤파린이 처리된 주사기를 사용하여 복대동맥으로부터 혈액을 채취한 후 채취한 혈액을 즉각 3000rpm에서 10분 동안 원심분리하여 상층의 혈장을 얻어 CO2 및 pH 측정에 이용하였다.
② Blood collection for blood CO 2 and pH measurement : 24 hours after alcohol administration, open the blood and collect the blood from the abdominal aorta using a heparin-treated syringe, and then collect the blood immediately at 3000 rpm for 10 minutes. The upper plasma was obtained by centrifugation and used for measuring CO 2 and pH.
③ 혈중 젖산( lactate ) 측정용 혈액채취 : 알코올을 투여한 후 24시간이 경과한 뒤에 개복하여 복대정맥으로부터 혈액을 채취한 후 글루코오스 대사(glucose metabolism)의 결과에 의해 증가하는 젖산을 막기 위하여 즉시 3M 과염소산(perchloric acid)을 처리하고 3000rpm에서 10분 동안 원심분리하여 상층의 제단백된 혈청을 얻어 젖산 측정에 이용하였다.
③ Blood sampling for measuring lactate in blood : 3M after taking alcohol and taking blood from the abdominal vein after 24 hours, 3M immediately to prevent the increase of lactic acid as a result of glucose metabolism. Perchloric acid (perchloric acid) was treated and centrifuged at 3000rpm for 10 minutes to obtain the upper protein-retained serum was used for lactic acid measurement.
④ 혈중 AST , ALT 및 r- GTP 측정용 혈액채취 : 알코올을 투여한 후 24시간이 경과한 뒤에 개복하여 복대정맥으로부터 혈액을 채취한 후 채취한 혈액을 3000rpm에서 10분 동안 원심분리하여 상층의 혈청을 얻어 AST, ALT 및 r-GTP 측정에 이용하였다.
④ Blood AST , ALT, and r- GTP measurement blood collection : 24 hours after alcohol administration, open the blood and collect the blood from the abdominal vein and centrifuged at 3000rpm for 10 minutes Were obtained and used for AST, ALT and r-GTP measurements.
<< 실험예Experimental Example 3> 3>
클로렐라-허브 혼합액이 혈중 Chlorella-Herb Mixture in Blood 알콜Alcohol 농도에 미치는 영향 Impact on concentration
본 발명자들은 본 발명의 제조예 1에서 제조한 클로렐라-허브 혼합액과 기존 숙취해소제가 숙취현상 중의 하나인 혈중 알코올 농도의 변화에 미치는 영향을 비교분석하였다. 이를 위해 상기 실험예 <2-2>에서 분리한 혈청으로부터 알코올 측정 키트(BioAssay-ECET100)를 사용하여 혈청 내 알코올 농도 변화 추이를 측정하였다.The present inventors compared and analyzed the effect of the chlorella-hub mixed solution prepared in Preparation Example 1 of the present invention and the existing hanger on the change of blood alcohol concentration, which is one of the hangover phenomena. To this end, the alcohol concentration kit (BioAssay-ECET100) was measured from the serum separated in Experimental Example <2-2> and the change in serum alcohol concentration was measured.
상기 알코올 측정 키트는 알코올 탈수소효소(alcohol dehydrogenase)가 알코올을 산화하면서 형성하는 NADH에 의해 포마잔 MTT chromogen이 발색되는 것을 565nm 흡광도로 측정하여 정량하는 원리를 따른다. 준비된 혈청 10㎕을 96웰 플레이트에 로딩한 후 반응시약 90㎕을 넣고 30분 동안 실온에 두었다가 반응정지 시약(stop reagent)을 100㎕ 넣어 반응을 정지시킨 후 565nm 흡광도에서 측정하였다.The alcohol measurement kit follows a principle of measuring and quantifying formazan MTT chromogen by 565 nm absorbance by NADH, which is formed by alcohol dehydrogenase oxidizing alcohol. 10 μl of the prepared serum was loaded into a 96-well plate, 90 μl of the reaction reagent was added thereto, and placed at room temperature for 30 minutes. Then, 100 μl of the stop reagent was added to stop the reaction.
그 결과, 하기 표 3에 나타낸 바와 같이, 대조군인 물+알코올 섭취군은 알코올 섭취 후 3시간 후에는 혈중 알코올 농도가 10.12±1.23(mM)까지 증가하였다가 5시간 후에 조금 감소하고 있는 것으로 나타났으며, 클로렐라-허브 혼합액+알코올 섭취군은 알코올 섭취 1시간, 3시간, 5시간 후 어느 시간에서도 혈중 알코올 농도가 낮게 유지되고 있음을 확인할 수 있었다.As a result, as shown in Table 3, the water + alcohol intake group as a control group showed that the blood alcohol concentration increased to 10.12 ± 1.23 (mM) after 3 hours after alcohol intake and then decreased slightly after 5 hours. In addition, the chlorella-herb mixture + alcohol intake group was confirmed that the blood alcohol concentration is maintained low at any time after 1 hour, 3 hours, 5 hours of alcohol intake.
이러한 결과를 통해 본 발명에 따른 클로렐라-허브 혼합액은 알코올의 섭취에 의해 증가되는 혈중의 알코올 농도를 감소시키는 효과가 있음을 알 수 있었다. 특히, 클로렐라-허브 혼합액은 기존의 숙취해소제인 C제품, Y제품 및 M제품보다도 혈중의 알코올 농도를 더욱 더 강하게 감소시키는 효능을 가지고 있음을 알 수 있었다. 이는 클로렐라-허브 혼합액이 알코올이 혈액으로 흡수되는 것을 억제시키거나 흡수를 지연시키기 때문에 혈액 중 알코올 농도가 낮아지게 될 것으로 추측되었다.
These results indicate that the chlorella-hub mixture according to the present invention has an effect of reducing the alcohol concentration in the blood increased by ingestion of alcohol. In particular, the chlorella-herb mixture was found to have an effect of more strongly reducing the alcohol concentration in the blood than conventional hangover C products, Y products and M products. It was speculated that the chlorella-hub mixture would lower the alcohol concentration in the blood because it inhibited or delayed absorption of the alcohol into the blood.
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, *는 물+알콜군과 비교하여 p<0.05, **는 p<0.001을 나타냄.
Data are expressed as mean ± SD (n = 3), where * indicates p <0.05 and ** indicates p <0.001 compared to the water + alcohol group.
<< 실험예Experimental Example 4> 4>
클로렐라-허브 혼합액이 혈액의 산성화에 미치는 영향Effect of Chlorella-Herb Mixture on Acidification of Blood
본 발명자들은 본 발명의 제조예 1에서 제조한 클로렐라-허브 혼합액이 혈액의 산성화에 미치는 영향을 확인하고자, 혈중 이산화탄소(CO2)의 농도, 혈중 탄산이온(HCO3 -)의 농도, 혈중 pH, 혈중 젖산의 농도의 변화를 살펴보았다.
The present inventors, in order to confirm the effect of the chlorella-hub mixture prepared in Preparation Example 1 of the present invention on the acidification of blood, the concentration of carbon dioxide (CO 2 ) in the blood, the concentration of carbonate ion (HCO 3 − ), blood pH, The changes in the concentration of lactic acid in the blood were examined.
<4-1> 혈중 이산화탄소(<4-1> carbon dioxide in the blood ( COCO 22 )의 농도에 미치는 영향 Effect on concentration
혈중의 이산화탄소(CO2)는 세포가 글루코오스 등의 유기물을 이용하여 그 자신의 생존에 필요한 에너지 등을 생성한 후에 생성되는 최종산물로서 혈액 중에 CO2가 증가하면 혈액의 pH가 산성화되는 원인이 되고, 호흡장해 및 편두통을 일으킨다. 또한 혈액 중의 CO2는 물(H2O)과 결합하여 H2CO3(탄산)이 된다. 즉 CO2 + H2O → H2CO3가 된다. 이 화학반응을 살펴보면 CO2가 증가하면 할수록 H2O의 소비가 증가한다는 것을 알 수 있다. Carbon dioxide (CO 2 ) in the blood is the final product produced after cells produce the energy necessary for their own survival by using organic materials such as glucose. When CO 2 increases in the blood, the pH of the blood becomes acidified. Produces respiratory disorders, and migraines. In addition, CO 2 in the blood combines with water (H 2 O) to form H 2 CO 3 (carbonate). CO 2 + H 2 O → H 2 CO 3 It becomes. Examination of this chemical reaction shows that as CO 2 increases, the consumption of H 2 O increases.
물의 소비는 갈증을 느끼게 하는 원인이고, 알코올의 섭취 후 갈증을 느끼는 것은 CO2의 증가에 의한 H2O의 소비의 증가가 원인이 된다. 그래서 혈액중의 CO2농도변화는 혈액중의 pH변화, 물의 소비변화, 갈증, 호흡장해 및 편두통의 임상적 평가지표가 된다.Consumption of water causes thirst, and thirst after ingestion of alcohol results in increased consumption of H 2 O by an increase in CO 2 . Thus, changes in the concentration of CO 2 in the blood are clinical indicators of changes in pH, blood consumption, thirst, respiratory distress and migraine headaches.
따라서 본 발명자들은 클로렐라-허브 혼합액과 기존 숙취해소제가 알코올의 섭취에 의해 증가되는 혈중 이산화탄소의 농도증가에 미치는 영향을 비교 분석하였다. 이를 위해 상기 실험예 <2-2>에서 알코올 투여 후 24시간 후에 채취한 혈장으로부터 CO2 분석 키트(Randox-CD129)를 사용하여 혈중 CO2 농도를 측정하였다.Therefore, the present inventors compared and analyzed the effect of the chlorella-hub mixture and the conventional hangover relieving agent on the increase in blood carbon dioxide concentration by the ingestion of alcohol. To this end, using a CO 2 assay kit (Randox-CD129) from the blood plasma collected 24 hours after the administration of alcohol in Experimental Example <2-2> was measured in the blood concentration of CO 2.
상기 CO2 분석 키트는 혈중의 중탄산염(bicarbonate)에 비례하여 옥살 아세트산(oxaloacetate)이 환원되고 이를 말레이트(malate)로 환원시킬 때 감소하는 NADH의 감소량을 340nm 흡광도로 측정하여 정량하는 원리를 따른다. 준비된 혈장 5㎕에 반응시약 1㎖을 첨가하여 5분 동안 37℃에서 반응시킨 후 340nm에서 흡광도를 측정하였다.The CO 2 assay kit follows the principle of quantifying by measuring 340 nm absorbance the amount of decrease in NADH that is reduced when oxaloacetate is reduced in proportion to bicarbonate in the blood and reduced to malate. 1 ml of the reaction reagent was added to 5 µl of the prepared plasma and reacted at 37 ° C. for 5 minutes, and the absorbance was measured at 340 nm.
그 결과, 하기 표 4에 나타낸 바와 같이, 알코올 섭취군(물+알코올 섭취군)은 알코올을 섭취하지 않은 정상 대조군의 혈액 내 CO2 농도(18.92±0.16mM)보다 8% 증가하여 20.43±0.77mM이 존재하고 있는 것으로 나타났으나, 기존의 숙취해소제(C제품, Y제품, M제품) 섭취군 및 클로렐라-허브 혼합액 섭취군의 혈액 중의 CO2 농도는 알코올 섭취군의 혈액 중의 CO2 농도(20.43±0.77mM)보다 낮은 농도로 유지하는 것으로 나타났다. 특히, 본 발명의 클로렐라-허브 혼합액을 섭취한 경우에는 대조군의 CO2농도(18.92±016mM)보다도 더 낮은 농도(18.03±0.72mM)로까지 혈액 중의 CO2 농도를 낮추는 것으로 나타났으며, 이를 통해 알코올 섭취 후 증가된 혈액중의 CO2 농도를 가장 강하게 감소시키는 효과가 있음을 알 수 있었다.
As a result, as shown in Table 4, the alcohol intake group (water + alcohol intake group) is the CO 2 in the blood of the normal control group that did not consume alcohol It was found that 20.43 ± 0.77mM existed by 8% increase from the concentration (18.92 ± 0.16mM), but the hunger killer (C product, Y product, M product) group and chlorella-hub mixed group group CO 2 in the blood The concentration is CO 2 in the blood of the alcoholic group. It was found to be maintained at a concentration lower than the concentration (20.43 ± 0.77 mM). In particular, when the chlorella-hub mixture of the present invention is ingested, CO 2 in the blood is lowered to a concentration lower than the control group's CO 2 concentration (18.92 ± 016mM) (18.03 ± 0.72mM). It was found that the concentration was lowered, and this resulted in the strongest effect of reducing the concentration of CO 2 in the blood after alcohol consumption.
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, *는 물+알콜군과 비교하여 p<0.05, **는 p<0.001을 나타냄.
Data are expressed as mean ± SD (n = 3), where * indicates p <0.05 and ** indicates p <0.001 compared to the water + alcohol group.
<4-2> 혈중 <4-2> blood 탄산이온(HCOCarbonate ions (HCO 33 -- )의)of 농도에 미치는 영향 Impact on concentration
한편, 혈액 중의 탄산이온(HCO3 -)은 혈액 중의 CO2의 농도에 비례하며, 이것은 CO2 + H2O → H2CO3 → HCO3 - + H+의 화학평형반응에서 알 수 있다. 탄산이온(HCO3 -) 농도는 하기 식 1로부터 계산하였다.
On the other hand, carbonate ions in the blood (HCO 3 -) is proportional to the concentration of CO 2 in the blood, and this CO 2 + H 2 O → H 2 CO 3 → HCO 3 - can be seen from the chemical equilibrium reactions + H +. Carbonate ion (HCO 3 -) concentration was calculated from the following equation 1.
(식 1)(Equation 1)
그 결과 하기 표 5에 나타낸 바와 같이, 알코올 섭취군에서는 정상 대조군의 탄산이온 농도(18.61±0.15mM)보다 7.8% 증가하여 20.06±0.76mM의 탄산이온이 존재하고 있는 것으로 나타났으며, 이것은 알코올 섭취군에서 혈중 CO2의 농도가 정상 대조군의 혈중 CO2의 농도보다 더 많이 증가했던 결과를 반영한다. 그러나, 클로렐라-허브 혼합액은 알코올 섭취에 의해 증가된 탄산이온의 농도를 강력하게 감소시키는 것으로 나타났다. 이러한 결과는 클로렐라-허브 혼합액이 혈중 이산화탄소의 농도를 가장 강하게 감소시키는 효과(표 4 참조)와 일치한다.
As a result, as shown in Table 5 below, the alcohol intake group was found to be 7.8% higher than the carbonate concentration (18.61 ± 0.15 mM) of the normal control group, indicating that 20.06 ± 0.76 mM carbonate was present. It reflects the result that the concentration of CO 2 increased serum than blood levels of CO 2 in the control group in the group. However, chlorella-hub mixtures have been shown to strongly reduce the concentration of carbonate ions increased by alcohol intake. This result is consistent with the effect of the chlorella-hub mixture having the strongest reduction in the concentration of carbon dioxide in the blood (see Table 4).
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, *는 물+알콜군과 비교하여 p<0.05, **는 p<0.001을 나타냄.
Data are expressed as mean ± SD (n = 3), where * indicates p <0.05 and ** indicates p <0.001 compared to the water + alcohol group.
<4-3> 혈중 <4-3> blood pHpH 에 미치는 영향Effect on
혈액의 pH는 혈액의 이산화탄소(CO2) 및 탄산이온(HCO3-)의 농도에 의해 변한다. 상기 (식 1)의 pH 계산공식에서 알 수 있듯이 알코올 섭취에 의해 혈액 중의 CO2농도가 증가하고, HCO3 -농도가 증가하면, 혈액의 pH는 산성으로 변하게 된다. 이와 같은 혈액 pH가 산성으로 변화된 임상증상을 호흡성 산혈증(acidosis)이라 하며, 이 경우 호흡곤란, 두통 등의 증상이 일어나게 된다.The pH of the blood is changed by the concentration of carbon dioxide (CO 2 ) and carbonate (HCO 3 − ) in the blood. As can be seen from the pH calculation formula of Equation 1, when the CO 2 concentration in the blood is increased by the ingestion of alcohol, and the HCO 3 − concentration is increased, the pH of the blood is changed to acidic. The clinical symptoms of such a change in blood pH are called respiratory acidosis, in which case respiratory distress and headaches occur.
따라서 본 발명자들은 클로렐라-허브 혼합액과 기존 숙취해소제가 알코올의 섭취에 의해 변화하는 혈중 pH 변화에 미치는 영향을 비교 분석하였다. 이를 위해 상기 실험예 <2-2>에서 알코올 투여 후 24시간 후에 채취한 혈장으로부터 pH meter (Schott-SRDC22N:1010)를 사용하여 혈중 pH를 측정하였다.Therefore, the present inventors compared and analyzed the effect of the chlorella-hub mixture and the existing hangover relievers on the blood pH change by the intake of alcohol. To this end, blood pH was measured using a pH meter (Schott-SRDC22N: 1010) from plasma collected 24 hours after alcohol administration in Experimental Example <2-2>.
그 결과, 하기 표 6에 나타낸 바와 같이, 정상 대조군의 혈중 pH는 7.88±0.01이지만, 알코올 섭취군은 알코올 섭취에 의해 pH가 7.83±0.01로 떨어져 혈액의 pH가 산성으로 변하였으며, 이것은 알코올 섭취로 인해 혈액 수소이온(H+) 농도가 정상 대조군의 혈액 수소이온(H+) 농도(13.18nM)보다 1610pM 증가되어 14.79nM로 나타난 결과를 반영한다. 그러나, 클로렐라-허브 혼합액과 기존의 숙취해소제(C제품, Y제품)의 섭취는 알코올 섭취에 의해 증가된 수소이온의 농도를 감소시킴으로써 알코올에 의해 산성화된 혈액의 pH를 증가시켜 정상군의 pH 상태로 회복시키는 것으로 나타났다. 특히, 클로렐라-허브 혼합액은 알코올 섭취에 의해 산성화된 pH(7.83±0.01)를 정상 대조군의 pH(7.88±0.01)와 비슷한 수준인 7.88±0.02로 회복시키는 것으로 나타나 기존의 숙취해소제들(C제품, Y제품, M제품) 보다도 더 효과적으로 수소이온의 농도를 감소시키는 것을 확인할 수 있었다.
As a result, as shown in Table 6, the blood pH of the normal control group is 7.88 ± 0.01, but in the alcohol intake group, the pH was decreased to 7.83 ± 0.01 by the ingestion of alcohol, and the pH of the blood was changed to acidic. Due to this, the blood hydrogen ion (H + ) concentration is increased by 1610pM than the blood hydrogen ion (H + ) concentration (13.18 nM) of the normal control, reflecting the results shown as 14.79 nM. However, ingestion of chlorella-herb mixture and conventional hangover relievers (C and Y products) increased the pH of the acidified blood by alcohol by decreasing the concentration of hydrogen ions increased by alcohol intake. Appeared to recover. In particular, the chlorella-hub mixture has been shown to restore acidified pH (7.83 ± 0.01) to 7.88 ± 0.02, similar to the pH of the normal control group (7.88 ± 0.01) by alcohol intake. , Y product, M product) was found to reduce the concentration of hydrogen ions more effectively.
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, *는 물+알콜군과 비교하여 p<0.05, **는 p<0.001을 나타냄.
Data are expressed as mean ± SD (n = 3), where * indicates p <0.05 and ** indicates p <0.001 compared to the water + alcohol group.
<4-4> 혈중 젖산(<4-4> Lactic acid in the blood ( lactatelactate )의 농도에 미치는 영향Effect on concentration
알코올을 섭취하게 되면 뇌에서 많은 양의 당(glucose)을 소비하게 되고, 이 결과 CO2의 생성이 증가됨으로서 혈중의 CO2 농도가 증가하여 혈액의 pH가 산성화됨과 동시에 혈액 중의 당 농도가 정상보다 낮아지는 저혈당 현상이 일어나게 된다. 저혈당 현상을 보충하기 위해 생체 내에서는 새로운 당을 생성시키는 반응이 진행되는데, 이 새로운 당의 생성에 이용되는 것이 젖산(lactate)이다. 혈액 중의 젖산이 증가하면 혈액 중에 수소이온농도(H+)가 증가하고, 이것에 의해 혈액의 pH는 산성으로 변하며, 이와 같은 병리현상을 젖산 산혈증(lactic acidosis)이라 하며 구토, 현기증, 호흡장해 및 두통이 일어나게 된다. 이러한 임상증상도 숙취현상 중의 하나이므로 본 발명자들은 혈액 중의 젖산 농도를 측정하였다.When intake of alcohol and consume a large amount (glucose) sugar in the brain, the resulting concentration than in normal sugar in the blood at the same time as increasing the blood in CO 2 concentration by being the generation of CO 2 increases the pH of the blood acidified by Lowering hypoglycemia occurs. In order to compensate for the hypoglycemic phenomenon, a reaction to generate new sugars in vivo proceeds, and lactate is used to generate new sugars. Increasing the amount of lactic acid in the blood increases the concentration of hydrogen ions (H + ) in the blood, which causes the pH of the blood to become acidic. This pathology is called lactic acidosis, which causes vomiting, dizziness, respiratory distress, You will have a headache. This clinical symptom is also one of the hangover phenomenon, the present inventors measured the lactic acid concentration in the blood.
따라서 본 발명자들은 클로렐라-허브 혼합액과 기존 숙취해소제가 알코올의 섭취에 의해 변화하는 혈중 pH 변화에 미치는 영향을 비교 분석하였다. 이를 위해 상기 실험예 <2-2>에서 채취한 제단백된 혈청으로부터 젖산 농도를 측정하였다.Therefore, the present inventors compared and analyzed the effect of the chlorella-hub mixture and the existing hangover relievers on the blood pH change by the intake of alcohol. To this end, the concentration of lactic acid was measured from the deproteinized serum collected in Experimental Example <2-2>.
젖산이 젖산 탈수소 효소(lactate dehydrogenase)에 의해 산화되면서 형성하는 NADH의 증가량을 340nm흡광도로 측정하여 정량하였으며, 단백질을 제거한 혈청 50㎕에 반응시약 1450㎕을 첨가하여 30분 동안 실온에서 반응시킨 후 340nm에서 흡광도를 측정하였다. The amount of NADH formed as lactic acid was oxidized by lactate dehydrogenase was measured by 340 nm absorbance. Absorbance was measured at.
그 결과 하기 표 7에 나타낸 바와 같이, 정상 대조군의 혈액 중에는 40.40±3.37(μM)의 젖산이 존재하지만 알코올 섭취군은 알코올 섭취에 의해 대조군보다 47.7% 증가하여 59.66±6.07(μM)의 젖산이 존재하는 것으로 나타났다. 그러나, 클로렐라-허브 혼합액과 기존의 숙취해소제(C제품, Y제품, M제품)는 알코올 섭취에 의해 증가된 혈중 젖산 농도를 감소시키는 것으로 나타났다. 특히, 본 발명의 클로렐라-허브 혼합액은 정상 대조군보다도 더 낮은 젖산 농도를 나타내어 효과적으로 혈중의 젖산 농도를 낮게 유지시키는 효과가 있음을 확인할 수 있었다.
As a result, as shown in Table 7 below, 40.40 ± 3.37 (μM) of lactic acid was present in the blood of the normal control group, but the alcohol intake group increased 47.7% than the control group by alcohol intake, resulting in 59.66 ± 6.07 (μM) lactic acid. Appeared to be. However, chlorella-hub mixtures and conventional hangover relievers (C, Y and M products) have been shown to reduce blood lactate concentrations increased by alcohol consumption. In particular, the chlorella-hub mixed solution of the present invention showed a lower lactic acid concentration than the normal control, it was confirmed that the effect of effectively maintaining the blood lactate concentration low.
증감량 (μM)lactate concentration
Increase / Decrease (μM)
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, *는 물+알콜군과 비교하여 p<0.05, **는 p<0.001을 나타냄.
Data are expressed as mean ± SD (n = 3), where * indicates p <0.05 and ** indicates p <0.001 compared to the water + alcohol group.
<< 실험예Experimental Example 5> 5>
클로렐라-허브 혼합액이 간기능 장해 임상지표에 미치는 영향Effect of Chlorella-Herb Mixture on Clinical Indicators of Liver Disorder
본 발명자들은 본 발명의 제조예 1에서 제조한 클로렐라-허브 혼합액이 간기능 장해 임상지표에 미치는 영향을 확인하고자, 혈중 AST, ALT, r-GTP의 변화를 살펴보았다.
The present inventors examined the changes in blood AST, ALT, r-GTP in order to determine the effect of the chlorella-hub mixed solution prepared in Preparation Example 1 of the present invention on clinical indicators of liver failure.
<5-1> 혈중 <5-1> blood ASTAST 의 활성에 미치는 영향Effect on the activity of
AST는 아스파르트산(aspartic acid)에 있는 아미노기(-NH2)를 알파케토글루타르산(α-ketoglutaric acid)의 카르보닐기(C=O)에 전이시켜 아스파르트산은 옥살 아세트산(oxaloacetic acid)으로, 알파케토글루타르산은 글루타민산으로 변하게 한다. 간세포막 인지질의 산화에 의해 세포막이 손상될 때 간 세포 내에 있는 AST가 혈액으로 분비되므로 혈중 AST는 간 손상 지표로 이용되며 이때에 glucose 신생저하에 의해 에너지가 충분히 생성되지 않아 전신 권태, 피로 등의 임상증상과 NADH/NADPH/글루타티온의 생성저하에 의한 세포 및 신체의 기능저하 및 독성이 없는 urea의 생성저하에 의한 암모니아 축적으로 혼수상태 등이 일어난다. AST transfers the amino group (-NH 2 ) in aspartic acid to the carbonyl group (C = O) of alpha-ketoglutaric acid, and aspartic acid is oxaloacetic acid. Glutaric acid turns into glutamic acid. When the cell membrane is damaged by the oxidation of hepatic phospholipids, AST in the liver cells is secreted into the blood. Therefore, blood AST is used as an indicator of liver damage. Clinical symptoms and degeneration of NADH / NADPH / glutathione result in coma due to ammonia accumulation due to cell and body deterioration and urea degeneration without toxicity.
따라서 본 발명자들은 클로렐라-허브 혼합액과 기존 숙취해소제가 간 손상 지표 중 하나인 AST의 변화에 미치는 영향을 비교 분석하였다. 이를 위해 상기 실험예 <2-2>에서 채취한 혈청으로부터 AceChem AST 키트(영동-A301)를 사용하여 혈중 AST를 측정하였다. 상기 측정 키트는 혈중 AST에 의해 생성된 옥살아세테이트(Oxaloacetate)를 말레이트로 환원시킬 때 감소하는 NADH의 감소량을 340nm 흡광도에서 kinetic으로 측정하여 효소반응식으로 계산하는 원리를 따른다.Therefore, the present inventors compared and analyzed the effects of the chlorella-hub mixture and the conventional hangover on the change of AST, one of the indicators of liver damage. To this end, blood AST was measured from the serum collected in Experimental Example <2-2> using AceChem AST kit (Dongdong-A301). The measurement kit follows the principle of kinetic measurement at 340 nm absorbance to reduce the amount of NADH that decreases when reducing oxalacetate produced by blood AST to malate.
준비된 혈청 100㎕에 반응시약 1㎖을 첨가하여 2분 동안 37℃에서 반응시킨 후 340nm에서 흡광도를 2분 동안 kinetic으로 측정하였다.1 mL of the reaction reagent was added to 100 μl of the prepared serum and reacted at 37 ° C. for 2 minutes, followed by kinetic measurement of absorbance at 340 nm for 2 minutes.
그 결과 하기 표 8에 나타낸 바와 같이, 알코올 섭취군에서는 109.32±4.36(U/L)으로 정상 대조군의 40.07±0.51(U/L)보다 173% 증가하였으며, 클로렐라-허브 혼합액은 65.42±1.77(U/L)로 알코올 섭취에 의해 증가된 혈중 AST 농도를 40.16% 감소시켰다. 특히, 혈중 AST 농도를 감소시키는 효과에 있어서 클로렐라-허브 혼합액은 기존의 숙취해소제인 C제품, Y제품 및 M제품보다 14% 이상 강력하게 혈중 AST를 감소시키는 것으로 나타났다. 이를 통해 본 발명의 클로렐라-허브 혼합액이 기존의 숙취해소제들(C제품, Y제품, M제품)에 비하여 간 보호효과에서 우수하다는 것을 확인할 수 있었다.
As a result, as shown in Table 8 below, the alcohol intake group was 109.32 ± 4.36 (U / L), which was 173% higher than the 40.07 ± 0.51 (U / L) of the normal control group, and the chlorella-herb mixture was 65.42 ± 1.77 (U). / L) reduced the blood AST concentration increased by 40.16% by alcohol intake. In particular, in the effect of reducing blood AST concentration, chlorella-herb mixture was found to reduce blood AST by more than 14% more strongly than conventional products C, Y and M products. Through this, it was confirmed that the chlorella-herbal mixture of the present invention is superior in the liver protection effect compared to the conventional hangover relievers (C products, Y products, M products).
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, *는 물+알콜군과 비교하여 p<0.05, **는 p<0.001을 나타냄.
Data are expressed as mean ± SD (n = 3), where * indicates p <0.05 and ** indicates p <0.001 compared to the water + alcohol group.
<5-2> 혈중 <5-2> blood ALTALT 의 활성에 미치는 영향Effect on the activity of
ALT는 알라닌에 있는 아미노기(-NH2)를 알파케토글루타르산의 카르보닐기(C=O)에 전이시켜 알라닌은 피루브산으로, 알파케토글루타르산은 글루타민산으로 변하게 한다. 간세포막 인지질의 산화에 의해 세포막이 손상될 때 간 세포 내에 있는 ALT가 혈액으로 분비되므로 혈중 ALT는 간 손상 지표로 이용되며 이때에 glucose 신생저하에 의해 에너지가 충분히 생성되지 않아 전신 권태, 피로 등의 임상증상과 NADH/NADPH/글루타티온의 생성저하에 의한 세포 및 신체의 기능저하 및 독성이 없는 우레아의 생성저하에 의한 암모니아 축적으로 혼수상태 등이 일어난다. ALT transfers the amino group (-NH 2 ) in alanine to the carbonyl group (C = O) of alpha ketoglutaric acid, converting alanine to pyruvic acid and alpha ketoglutaric acid to glutamic acid. When the cell membrane is damaged by the oxidation of hepatocellular phospholipid, ALT in the liver cells is secreted into the blood, so blood ALT is used as an indicator of liver damage. The coma is caused by the accumulation of ammonia due to the deterioration of the cell and body due to the clinical symptoms and the reduced production of NADH / NADPH / glutathione and the production of urea which is not toxic.
따라서 본 발명자들은 클로렐라-허브 혼합액과 기존 숙취해소제가 간 손상 지표 중 하나인 ALT의 변화에 미치는 영향을 비교 분석하였다. 이를 위해 상기 실험예 <2-2>에서 채취한 혈청으로부터 AceChem ALT 키트(영동-A302)를 사용하여 혈중 ALT를 측정하였다. 상기 측정 키트는 혈중 ALT에 의해 생성된 피루브산을 젖산으로 환원시킬 때 감소하는 NADH의 감소량을 340nm 흡광도에서 kinetic으로 측정하여 효소반응식으로 계산하는 원리를 따른다.Therefore, the present inventors compared and analyzed the effect of the chlorella-hub mixture and the conventional hangover on the change of ALT which is one of the indicators of liver damage. To this end, blood ALT was measured from the serum collected in Experimental Example <2-2> using AceChem ALT kit (Dongdong-A302). The measurement kit follows the principle of kinetic measurement of the amount of reduction of NADH, which is reduced when reducing pyruvate produced by blood ALT to lactic acid, at 340 nm absorbance.
준비된 혈청 100㎕에 반응시약 1㎖을 첨가하여 2분 동안 37℃에서 반응시킨 후 340nm에서 흡광도를 2분 동안 kinetic으로 측정하였다.1 mL of the reaction reagent was added to 100 μl of the prepared serum and reacted at 37 ° C. for 2 minutes, followed by kinetic measurement of absorbance at 340 nm for 2 minutes.
그 결과 하기 표 9에 나타낸 바와 같이, 알코올 섭취군에서는59.23±3.85(U/L)으로 정상 대조군의 27.99±1.02(U/L)보다 112% 증가하였으며, 클로렐라-허브 혼합액은 32.12±0.51(U/L)로 알코올 섭취에 의해 증가된 혈중 ALT 농도를 45.77% 감소시켰다. 특히, 혈중 ALT 농도를 감소시키는 효과에 있어서 클로렐라-허브 혼합액은 기존의 숙취해소제인 C제품, Y제품 및 M제품보다 15% 이상 강력하게 혈중 ALT를 감소시키는 것으로 나타났다. 이는 클로렐라-허브 혼합액이 혈중 AST 농도를 감소시키는 효과(표 8 참조)와 일치한다. 이를 통해 본 발명의 클로렐라-허브 혼합액이 기존의 숙취해소제들(C제품, Y제품 및 M제품)에 비하여 간 보호효과에서 우수하다는 것을 확인할 수 있었다.
As a result, as shown in Table 9, in the alcohol intake group, 59.23 ± 3.85 (U / L) increased by 112% than the 27.99 ± 1.02 (U / L) of the normal control, Chlorella-Herb mixture 32.12 ± 0.51 (U / L) reduced the blood ALT concentration increased by 45.77% by alcohol intake. In particular, in the effect of reducing blood ALT concentration, chlorella-herb mixture was found to reduce blood ALT by more than 15% more powerfully than conventional products C, Y and M. This is consistent with the effect of chlorella-hub mixture on reducing blood AST concentrations (see Table 8). Through this, it was confirmed that the chlorella-hub mixed solution of the present invention is superior in the liver protection effect compared to the conventional hangover relievers (C products, Y products and M products).
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, *는 물+알콜군과 비교하여 p<0.05, **는 p<0.001을 나타냄.
Data are expressed as mean ± SD (n = 3), where * indicates p <0.05 and ** indicates p <0.001 compared to the water + alcohol group.
<5-3> 혈중 r-<5-3> blood r- GTPGTP 의 활성에 미치는 영향Effect on the activity of
r-GTP는 혈중에 있는 알라닌, 아르파르트산, 글루타민산 등의 AST, ALT의 기질아미노산, 산화를 억제시키는 글루타티온의 구성아미노산인 시스테인, 글리신, 글루타민산, 그리고 모든 단백질 합성에 필요한 아미노산을 간세포의 내부로 수송시키는 중요한 작용을 한다. 간세포막 인지질의 산화에 의해 세포막이 손상될 때 간 세포 내에 있는 r-GTP가 혈액으로 분비되므로 혈중 r-GTP는 간 손상 지표로 이용되며 이때에 glucose 신생저하에 의해 에너지가 충분히 생성되지 않아 전신 권태, 피로 등의 임상증상과 NADH/NADPH/글루타티온의 생성저하에 의한 세포 및 신체의 기능저하 및 독성이 없는 우레아의 생성저하에 의한 암모니아 축적으로 혼수상태 등이 일어난다. r-GTP contains ASTs such as alanine, aspartic acid and glutamic acid in the blood, substrate amino acids of ALT, constituent amino acids of antioxidant glutathione, cysteine, glycine, glutamic acid, and amino acids necessary for the synthesis of all proteins into the interior of liver cells. It is important to transport. When the cell membrane is damaged by the oxidation of hepatocellular phospholipids, r-GTP in the liver cells is secreted into the blood, so blood r-GTP is used as an indicator of liver damage. And coma due to ammonia accumulation due to clinical symptoms such as fatigue, decreased cellular and body function due to NADH / NADPH / glutathione production, and reduced urea production without toxicity.
따라서 본 발명자들은 클로렐라-허브 혼합액과 기존 숙취해소제가 간 손상 지표 중 하나인 r-GTP의 변화에 미치는 영향을 비교 분석하였다. 이를 위해 상기 실험예 <2-2>에서 채취한 혈청으로부터 AceChem r-GTP 키트(영동-A319)를 사용하여 혈중 r-GTP를 측정하였다. 상기 측정 키트는 혈중 r-GTP에 의해 생성되는 p-니트로아닐린의 증가량을 405nm 흡광도에서 kinetic으로 측정하여 효소반응식으로 계산하는 원리를 따른다. Therefore, the present inventors compared and analyzed the effects of chlorella-hub mixture and conventional hangover on the change of r-GTP which is one of the indicators of liver damage. To this end, blood r-GTP was measured from the serum collected in Experimental Example <2-2> using AceChem r-GTP kit (Dong-A319). The measurement kit follows the principle of calculating the amount of p-nitroaniline produced by r-GTP in the blood by kinetic measurement at 405 nm absorbance and calculating it by enzyme reaction.
준비된 혈청 500㎕에 반응시약 1㎖을 첨가하여 2분 동안 37℃에서 반응시킨 후 405nm에서 흡광도를 2분 동안 kinetic으로 측정하였다.1 mL of the reaction reagent was added to 500 μl of the prepared serum and reacted at 37 ° C. for 2 minutes, followed by kinetic measurement at 405 nm for 2 minutes.
그 결과 하기 표 10에 나타낸 바와 같이, 알코올 섭취군에서는13.43±0.61(U/L)로 정상 대조군의 10.96±0.61(U/L) 보다 22.5% 증가하였으며, 클로렐라-허브 혼합액은 10.87±0.53(U/L)으로 알코올 섭취에 의해 증가된 혈중 r-GTP 농도를 19.06% 감소시켰다. 특히, 혈중 r-GTP 농도를 감소시키는 효과에 있어서 클로렐라-허브 혼합액은 기존의 숙취해소제인 C제품, Y제품 및 M제품보다 8% 이상 강력하게 혈중 r-GTP를 감소시키는 것으로 나타났으며, 이는 정상대조군의 r-GTP 농도와 비슷한 수준이다. 이를 통해 본 발명의 클로렐라-허브 혼합액이 기존의 숙취해소제들에 비하여 간 보호효과에서 우수하다는 것을 확인할 수 있었다.
As a result, as shown in Table 10, in the alcohol intake group, 13.43 ± 0.61 (U / L) was increased by 22.5% than 10.96 ± 0.61 (U / L) of the normal control, the chlorella-hub mixture is 10.87 ± 0.53 (U / L) reduced the blood r-GTP concentration increased by 19.06% by alcohol intake. In particular, in the effect of reducing the concentration of r-GTP in the blood, chlorella-herb mixture was found to reduce blood r-GTP more than 8% more strongly than the existing products of hangover relievers C, Y and M products. It is similar to the r-GTP concentration of the normal control. Through this, it was confirmed that the chlorella-hub mixed solution of the present invention is superior in the liver protection effect compared to the conventional hangover relievers.
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, *는 물+알콜군과 비교하여 p<0.05, **는 p<0.001을 나타냄.
Data are expressed as mean ± SD (n = 3), where * indicates p <0.05 and ** indicates p <0.001 compared to the water + alcohol group.
따라서 상기와 같은 결과들을 통해 클로렐라 제품이 기존의 숙취해소제들에 비하여 강력하게 혈중 알코올 농도를 감소시키고, 이로 인해 발생할 수 있는 간 손상을 더욱 효과적으로 방어하였다는 결과를 얻었으므로 클로렐라 제품이 효과적인 숙취해소제로서 개발의 가능성이 충분하다는 것을 입증하였다.
Therefore, these results indicate that chlorella products reduce blood alcohol levels more strongly than conventional hangover cure agents, and thus more effectively defend against liver damage that may be caused by chlorella products. Zero proved the possibility of development.
<< 실시예Example 6> 6>
간의 알코올 산화효소 활성에 미치는 영향Effect on Liver Alcohol Oxidase Activity
알코올이 혈관을 거쳐 간의 문맥을 통해 간으로 유입되면 알코올 탈수소효소(alcohol dehydrogenase, 이하, ‘ADH’라고 함)에 의해 아세트알데하이드로 산화되고, ADH의 조효소(coenzyme)인 NAD+는 NADH로 환원된다. 이러한 아세트알데하이드는 알데하이드 탈수소효소(aldehyde dehydrogenase, 이하, ‘ALDH’라고 함)에 의해 아세테이트로 산화되면서, NAD+로부터 NADH가 생성된다. When alcohol enters the liver through the blood vessels through the blood vessels, it is oxidized to acetaldehyde by alcohol dehydrogenase (hereinafter referred to as 'ADH'), and NAD + , a coenzyme of ADH, is reduced to NADH. . This acetaldehyde is oxidized to acetate by aldehyde dehydrogenase (hereinafter referred to as 'ALDH'), whereby NADH is produced from NAD + .
ADH와 ALDH의 활성 증가는 아세트알데하이드의 축적을 막기 위한 피드백 현상이다. 장기간 알코올을 복용할 경우 간에서 알코올을 분해시키기 위하여 ADH와 ALDH의 활성이 증가하여 나타나며 그렇기 때문에 만성 알코올 중독의 중요한 지표로서 ADH와 ALDH의 활성이 이용된다. Increased activity of ADH and ALDH is a feedback phenomenon to prevent the accumulation of acetaldehyde. Long-term alcohol consumption increases the activity of ADH and ALDH to decompose alcohol in the liver. Therefore, the activity of ADH and ALDH is used as an important indicator of chronic alcoholism.
따라서 본 발명자들은 장기간(4주)알코올 음용으로 인한 간내 알코올 산화효소(탈수소효소)들의 변화에 대한 클로렐라 과립의 식이효과를 확인하기 위하여 상기 <제조예 2>에서 제조한 클로렐라-허브 과립을 이용하여 다음과 같은 식이실험을 진행하였다.
Therefore, the present inventors used the chlorella-hub granules prepared in Preparation Example 2 to confirm the dietary effect of chlorella granules on the changes of alcohol oxidase (dehydrogenase) in the liver due to long-term (4 weeks) alcohol consumption. The following dietary experiments were conducted.
<6-1> 클로렐라 과립의 식이 및 알코올의 투여<6-1> Diet of Chlorella Granules and Administration of Alcohol
8주령 SD 랫트에 일반사료 식이와 물을 음용시킨군(대조군), 클로렐라 과립이 3% 함유된 사료를 제조하여 식이하고 물을 음용시킨군(3% 클로렐라 섭취군), 일반사료 식이와 25% 알코올을 음용시킨군(25% 알코올 섭취군), 및 클로렐라 과립이 3% 함유된 사료를 식이하고 25% 알코올을 음용시킨군(3% 클로렐라 식이 + 25% 알코올 섭취군), 총 네 가지 그룹으로 나누어 4주 동안 식이실험을 진행하였다.
8-week-old SD rats were fed a diet diet and water (control), a feed containing 3% chlorella granules, and a diet and drinking water (3% chlorella intake), a diet and 25% diet. There were four groups of alcohol-drinks (25% alcohol) and 3% chlorella granules and 25% alcohol (3% Chlorella + 25% alcohol). The diet was conducted for 4 weeks.
<6-2> 알코올 탈수소효소(<6-2> alcohol dehydrogenase ( ADHADH ) 활성에 미치는 효과) Effect on activity
본 발명자들은 장기간 알코올 섭취 시에 일어나는 만성 알코올 중독의 억제에 미치는 클로렐라 식이의 효과를 확인하기 위해 간 내의 ADH 활성 변화를 측정하였다. ADH의 측정은 ADH에 의해 n-부탄올이 산화될 때 p-nitrosodiumethylaniline(NDMA)가 환원되어 발색이 감소되는 것을 440nm 흡광도에서 kinetic으로 측정하여 효소반응식으로 계산하는 원리를 따른다.We measured changes in ADH activity in the liver to ascertain the effect of the chlorella diet on the inhibition of chronic alcoholism that occurs upon prolonged alcohol intake. The measurement of ADH follows the principle of kinetic measurement at 440 nm absorbance that p-nitrosodiumethylaniline (NDMA) is reduced by oxidizing n-butanol by ADH and reduced color development.
준비된 샘플 100㎕에 반응시약 1.9㎖를 첨가하여 440nm에서 흡광도를 5분 동안 kinetic으로 측정하였다.1.9 ml of the reaction reagent was added to 100 µl of the prepared sample, and the absorbance at 440 nm was measured by kinetic for 5 minutes.
그 결과 하기 표 11에 나타낸 바와 같이, 25% 알코올 섭취군에서는 6.97±0.27 (nmol/minmg protein)로 대조군의 4.97±0.97 (nmol/minmg protein)보다 40.2% 증가하였으며, 3% 클로렐라+ 25% 알코올 섭취군은 4.03±0.09 (nmol/minmg protein)으로서 클로렐라의 식이로 인해 간 내 ADH 활성이 정상의 상태로 완전히 감소되었음을 알수있다.
As a result, as shown in Table 11 below, in the 25% alcohol intake group, 6.97 ± 0.27 (nmol / minmg protein) increased by 40.2% from 4.97 ± 0.97 (nmol / minmg protein) in the control group, and 3% chlorella + 25% alcohol. The intake group was 4.03 ± 0.09 (nmol / minmg protein), indicating that ADH activity in the liver was completely reduced to normal due to chlorella's diet.
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, **은 25% 알코올 섭취군과 비교하여 p<0.001을 나타냄.
Data presented as mean ± SD (n = 3), ** indicates p <0.001 compared to 25% alcohol intake group.
<6-3> 간의 <6-3> between 알데하이드Aldehyde 산화효소(탈수소효소) 활성에 미치는 효과 Effect on oxidase (dehydrogenase) activity
본 발명자들은 장기간 알코올 섭취 시에 일어나는 만성 알코올 중독의 억제에 미치는 클로렐라 식이의 효과를 확인하기 위해 간 내의 ALDH 활성 변화를 측정하였다. ALDH의 측정은 ALDH에 의해 아세트알데하이드가 산화될 때 6-methoxy-2-naphthaldehyde가 형광물질인 6-methoxy-2-naphthoic acid로 환원되면서 나오는 형광을 310/360nm 형광도에서 kinetic으로 측정하여 효소반응식으로 계산하는 원리를 따른다.We measured changes in ALDH activity in the liver to ascertain the effect of the chlorella diet on the inhibition of chronic alcoholism that occurs upon prolonged alcohol intake. ALDH was measured by kinetic measurement of fluorescence resulting from the reduction of 6-methoxy-2-naphthaldehyde to 6-methoxy-2-naphthoic acid, a fluorine when acetaldehyde was oxidized by ALDH. Follow the principle of calculation.
준비된 샘플 60㎕에 반응시약 2.94㎖를 첨가하여 excitation 310nm/ emission 360nm 에서 형광도를 3분 동안 kinetic으로 측정하였다.2.94 ml of reaction reagent was added to 60 µl of the prepared sample, and fluorescence was measured by kinetic for 3 minutes at excitation 310 nm / emission 360 nm.
그 결과 하기 표 12에 나타낸 바와 같이, 25% 알코올 섭취군에서의 ALDH의 활성은 0.288±0.016 (nmol/minmg protein)로 대조군의 0.224±0.011 (nmol/minmg protein)보다 28.6% 증가하였으며, 3% 클로렐라+ 25% 알코올 섭취군에서의 ALDH의 활성은 0.238±0.010 (nmol/minmg protein)이었다. 이것은 25% 알코올 섭취에 의해 대조군의 것보다 28.6% 증가한 ALDH의 활성이 클로렐라의 식이로 인해 완전히 저해되었음을 의미한다.
As a result, as shown in Table 12 below, ALDH activity in the 25% alcohol intake group was 0.288 ± 0.016 (nmol / minmg protein), 28.6% higher than 0.224 ± 0.011 (nmol / minmg protein) in the control group, and 3% ALDH activity in the Chlorella + 25% alcohol intake group was 0.238 ± 0.010 (nmol / minmg protein). This means that the activity of ALDH, which was 28.6% higher than that of the control group by 25% alcohol intake, was completely inhibited due to the diet of chlorella.
ㆍ데이터는 평균±SD(n = 3)로 나타내었으며, **은 25% 알코올 섭취군과 비교하여 p<0.001을 나타냄.
Data presented as mean ± SD (n = 3), ** indicates p <0.001 compared to 25% alcohol intake group.
따라서, 상기와 같은 결과를 통해 장기간 알코올 섭취로 인해 일어나는 만성 알코올 중독에서 클로렐라의 섭취가 알코올 중독을 개선시키는 효과가 있음을 확인하였다.
Therefore, it was confirmed from the above results that the intake of chlorella in chronic alcoholism caused by long-term alcohol intake has an effect of improving alcoholism.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far I looked at the center of the preferred embodiment for the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (11)
솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유로 이루어진 허브 추출물을 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 약학적 조성물.Chlorella extract; And
Pharmaceutical composition for improving liver function or hangover, comprising a herb extract consisting of pine needles, mulberry leaves, barley shoots, pumpkin, thorny ginseng, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion and cornus as an active ingredient.
솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유로 이루어진 허브 건조분말을 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 약학적 조성물.Dry powder of chlorella; And
Pharmaceutical composition for improving liver function or hangover, comprising a herb dry powder consisting of pine needles, mulberry leaves, barley shoots, pumpkin, thorny ginseng, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion and cornus as an active ingredient.
상기 조성물 전체 100중량부에 대하여 클로렐라 40 ~ 70 중량부, 솔잎 9 ~ 18 중량부, 뽕잎 4.5 ~ 10.5 중량부, 보리순 3 ~ 6 중량부, 호박 3 ~ 6 중량부, 가시오가피 1.5 ~ 3 중량부, 쑥 1.5 ~ 1.5 중량부, 어성초 1.5 ~ 3 중량부, 신선초 1.5 ~ 3 중량부, 익모초 1.5 ~ 3 중량부, 민들레 1.5 ~ 3 중량부 및 산수유 1.5 ~ 3 중량부인 것을 특징으로 하는 간기능 개선 또는 숙취해소용 약학적 조성물.3. The method according to claim 1 or 2,
Chlorella 40 to 70 parts by weight, pine needles 9 to 18 parts by weight, mulberry leaves 4.5 to 10.5 parts by weight, barley shoots 3 to 6 parts by weight, pumpkin 3 to 6 parts by weight, thorny skin 1.5 to 3 parts, Mugwort 1.5 ~ 1.5 parts by weight, Eoseongcho 1.5 ~ 3 parts by weight, fresh vinegar 1.5 ~ 3 parts by weight, motherwort 1.5 ~ 3 parts by weight, dandelion 1.5 ~ 3 parts by weight and cornus milk 1.5 ~ 3 parts by weight liver improvement or hangover Relieving pharmaceutical composition.
상기 추출물은 물 또는 유기용매로 추출하여 수득한 것임을 특징으로 하는 간기능 개선 또는 숙취해소용 약학적 조성물.The method of claim 1,
The extract is characterized in that obtained by extracting with water or an organic solvent, liver function improvement or hangover pharmaceutical composition.
상기 건조분말은 100℃ 이하의 온도에서 건조시켜 분말화한 것을 특징으로 하는 간기능 개선 또는 숙취해소용 약학적 조성물.3. The method of claim 2,
The dried powder is dried and dried at a temperature of less than 100 ℃ liver function improvement or hangover pharmaceutical composition characterized in that powdered.
상기 조성물은 혈중 이산화탄소의 농도를 감소시키는 활성, 혈중 pH를 증가시키는 활성 및 혈중 젖산 농도를 감소시키는 활성을 갖는 것을 특징으로 하는 간기능 개선 또는 숙취해소용 약학적 조성물.3. The method according to claim 1 or 2,
The composition of the present invention has an activity for reducing the concentration of carbon dioxide in the blood, an activity for increasing the pH in the blood, and a blood composition for improving liver function or hangover, characterized in that it has an activity for decreasing the concentration of lactic acid in the blood.
상기 조성물은 혈중의 AST, ALT 및 r-GTP 농도를 감소시키는 활성을 갖는 것을 특징으로 하는 간기능 개선 또는 숙취해소용 약학적 조성물.3. The method according to claim 1 or 2,
The composition is characterized in that it has an activity to reduce the concentration of AST, ALT and r-GTP in the blood liver improvement or hangover pharmaceutical composition.
상기 조성물은 알코올 탈수소효소(ADH)의 활성을 감소시키거나 알데하이드 탈수소효소(ALDH)의 활성을 감소시키는 것을 특징으로 하는 간기능 개선 또는 숙취해소용 약학적 조성물.3. The method according to claim 1 or 2,
The composition is characterized in that to reduce the activity of alcohol dehydrogenase (ADH) or reduce the activity of aldehyde dehydrogenase (ALDH), liver function improvement or hangover pharmaceutical composition.
솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유로 이루어진 허브 추출물을 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 건강기능식품.Chlorella extract; And
Health functional food for improving liver function or hangover, comprising herbal extracts consisting of pine needles, mulberry leaves, barley sprouts, pumpkins, thorny cucumbers, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion and cornus as active ingredients.
솔잎, 뽕잎, 보리순, 호박, 가시오가피, 쑥, 어성초, 신선초, 익모초, 민들레 및 산수유로 이루어진 허브 건조분말을 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 건강기능식품.Dry powder of chlorella; And
Health functional food for improving liver function or hangover, comprising herbal dry powder consisting of pine needles, mulberry leaves, barley shoots, pumpkin, thorny greens, mugwort, eoseongcho, fresh vinegar, motherwort, dandelion and cornus as active ingredients.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100106314A KR101371143B1 (en) | 2010-10-28 | 2010-10-28 | Composition comprising chlorella for improving liver function or relieving hangover |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100106314A KR101371143B1 (en) | 2010-10-28 | 2010-10-28 | Composition comprising chlorella for improving liver function or relieving hangover |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120044807A KR20120044807A (en) | 2012-05-08 |
KR101371143B1 true KR101371143B1 (en) | 2014-03-18 |
Family
ID=46264509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100106314A KR101371143B1 (en) | 2010-10-28 | 2010-10-28 | Composition comprising chlorella for improving liver function or relieving hangover |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101371143B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102180204B1 (en) | 2020-05-21 | 2020-11-18 | 최복남 | Manufacturing method of Kimchi for preventing diabetes and alcohol-based liver damage |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101483592B1 (en) * | 2012-11-20 | 2015-01-16 | 대한민국 | Decreasing Effect in Blood Ethanol Concentration and Improvement of Hepatic Function Including Preparation of Sprouts Hordeum Vulgare Extracts |
CN103110741A (en) * | 2012-12-22 | 2013-05-22 | 潘海燕 | Medicinal liquor for treating stomach illness |
CN104107350A (en) * | 2014-06-30 | 2014-10-22 | 胥玲 | Traditional Chinese medicinal preparation for treating nervous headaches |
KR101544570B1 (en) * | 2014-12-17 | 2015-08-13 | 주식회사 블루텍 | Beverage composition for eliminating hangover and improvement of hepatic function |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050047053A (en) * | 2005-04-19 | 2005-05-19 | 김영근 | Meal substitutes based on brown rice and various nutritional ingredients |
KR20070013965A (en) * | 2005-07-26 | 2007-01-31 | 김화란 | Chlorella A method for producing a dietary supplement (reproduction) based on 100% raw material. |
-
2010
- 2010-10-28 KR KR1020100106314A patent/KR101371143B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050047053A (en) * | 2005-04-19 | 2005-05-19 | 김영근 | Meal substitutes based on brown rice and various nutritional ingredients |
KR20070013965A (en) * | 2005-07-26 | 2007-01-31 | 김화란 | Chlorella A method for producing a dietary supplement (reproduction) based on 100% raw material. |
Non-Patent Citations (2)
Title |
---|
한국영양학회 2002년도 춘계학술대회, pp. 163-163. (2002) * |
황유경, Chlorella vulgaris 추출물의 간 해독 기전에 대한 연구, 인제대학교 대학원 박사학위논문 (2007) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102180204B1 (en) | 2020-05-21 | 2020-11-18 | 최복남 | Manufacturing method of Kimchi for preventing diabetes and alcohol-based liver damage |
Also Published As
Publication number | Publication date |
---|---|
KR20120044807A (en) | 2012-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102299934B1 (en) | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution | |
KR100615039B1 (en) | Method of oriental herbal yogurt | |
KR101959986B1 (en) | Composition of comprising vegetable worms extract cultured using mealworm or pupa and process of fabrication the extract | |
KR101930483B1 (en) | Smilax china leaf fermented with Aspergillus species and Extract of the same | |
KR101371143B1 (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
KR101919839B1 (en) | Composition for hepatoprotective and ameliorating hangover containing cricket material enzyme-decomposed with Alcalase | |
CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
KR101665584B1 (en) | Composition for eliminating hangover | |
KR101093998B1 (en) | Functional composition for the prevention of hangover and improving liver function | |
KR100976241B1 (en) | Extract of sedum sarmentosum for alcohol oxidation and relieves hangover | |
KR101819026B1 (en) | Composition for use of inhibition of stomach damage to alcohol or inhibition of alcohol uptake or relief of hangover comprising fermented extract of native plants from Jeju island | |
JP2006014730A (en) | Food product | |
KR102127411B1 (en) | Composition comprising natural complex extract for protecting liver and relieving hangover | |
KR20100003045A (en) | Composition for preventing or improving diabete comprising sun-dried salt and an extract of eclipta prostrata | |
KR20130130131A (en) | Vinegar composition fermented with black garlic and preparation method thereof | |
KR102433586B1 (en) | Food composition for relieving hangover and improving hepatic function | |
KR100977076B1 (en) | Anti-helicobacter composition containing schizandra sp extract and rubus careabus extract | |
KR101391647B1 (en) | Anti obesity composition | |
KR101962893B1 (en) | Composition of comprising vegetable worms extract cultured using mealworm or pupa and process of fabrication the extract | |
KR100540498B1 (en) | Hangover curing agent containing astaxanthin and aspartic acid | |
KR101725261B1 (en) | Composition for the dissolving of the alcohol consistencies in blood and the neutralizing poisons of the hangover | |
EP2052728B1 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia | |
KR101074348B1 (en) | Anti-helicobacter composition containing green algae extract | |
KR20180013603A (en) | Alcohol detoxification composition comprising extract of natural herb | |
KR100505764B1 (en) | Hangover curing agent containing astaxanthin, aspartic acid and extract from flowers of an arrowroot |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180102 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190107 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20200302 Year of fee payment: 7 |